<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Haematol</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Haematol</journal-id><journal-id journal-id-type="publisher-id">bjh</journal-id><journal-title-group><journal-title>British Journal of Haematology</journal-title></journal-title-group><issn pub-type="ppub">0007-1048</issn><issn pub-type="epub">1365-2141</issn><publisher><publisher-name>BlackWell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24935654</article-id><article-id pub-id-type="pmc">4282038</article-id><article-id pub-id-type="doi">10.1111/bjh.12981</article-id><article-categories><subj-group subj-group-type="heading"><subject>Reviews</subject></subj-group></article-categories><title-group><article-title>Progress and prospects for engineered T cell therapies</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Qasim</surname><given-names>Waseem</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Thrasher</surname><given-names>Adrian J</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref></contrib><aff id="au1"><label>1</label><institution>Molecular &#x00026; Cellular Immunology, Institute of Child Health, University College London</institution><addr-line>London, UK</addr-line></aff><aff id="au2"><label>2</label><institution>Great Ormond Street Hospital Trust</institution><addr-line>London, UK</addr-line></aff></contrib-group><author-notes><corresp id="cor1">
Correspondence: Dr Waseem Qasim, Molecular &#x00026; Cellular Immunology, Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK., E-mail: <email>W.Qasim@ucl.ac.uk</email></corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>17</day><month>6</month><year>2014</year></pub-date><volume>166</volume><issue>6</issue><fpage>818</fpage><lpage>829</lpage><permissions><copyright-statement>&#x000a9; 2014 The Authors. <italic>British Journal of Haematology</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Proof-of-concept studies have demonstrated the therapeutic potential of engineered T cells. Transfer of recombinant antigen-specific T cell receptors (TCR) and chimaeric antigen receptors (CARs) against tumour and viral antigens are under investigation by multiple approaches, including viral- and nonviral-mediated gene transfer into both autologous and allogeneic T cell populations. There have been notable successes recently using viral vector-mediated transfer of CARs specific for B cell antigens, but also reports of anticipated and unanticipated complications in these and other studies. We review progress in this promising area of cellular therapy, and consider developments in antigen receptor therapies including the application of emerging gene-editing technologies.</p></abstract><kwd-group><kwd>transplantation</kwd><kwd>T cells</kwd><kwd>gene therapy</kwd></kwd-group></article-meta></front><body><p>Whilst the application of tyrosine kinase inhibitors and antibody-based therapies has become rapidly established in haematological practice (<xref rid="b41" ref-type="bibr">Katsnelson, 2013</xref>), the use of cell-based therapies, particularly genetically engineered T cells, is still emerging. In recent months there have been a number of encouraging reports detailing the therapeutic application of genetically modified T cells. In particular, promising data from trials investigating T cells modified to express chimaeric antigen receptors (CARs) against B cell antigens have generated extensive interest from clinicians, researchers, pharmaceutical companies and investors (<xref rid="b34" ref-type="bibr">Humphries, 2013</xref>). Here we review progress in this field, consider the technologies involved and how these approaches are likely to be applied, and the hurdles faced in delivering cell and gene therapies.</p><p>The potency of T cell-mediated immunity against viruses and certain malignancies is now well established. In the haematological setting, adoptive transfer of T cells against viral pathogens, such as Epstein Barr Virus (EBV), Cytomegalovirus (CMV) and Adenovirus, has been of proven benefit in the allogeneic stem cell transplant (allo-SCT) setting (<xref rid="b92" ref-type="bibr">Walter <italic>et&#x000a0;al</italic>, 1995</xref>; <xref rid="b29" ref-type="bibr">Heslop <italic>et&#x000a0;al</italic>, 1996</xref>, <xref rid="b30" ref-type="bibr">2010</xref>; <xref rid="b66" ref-type="bibr">Peggs <italic>et&#x000a0;al</italic>, 2003</xref>, <xref rid="b67" ref-type="bibr">2011</xref>; <xref rid="b12" ref-type="bibr">Cobbold <italic>et&#x000a0;al</italic>, 2005</xref>; <xref rid="b21" ref-type="bibr">Feuchtinger <italic>et&#x000a0;al</italic>, 2006</xref>; <xref rid="b48" ref-type="bibr">Leen <italic>et&#x000a0;al</italic>, 2009</xref>; <xref rid="b72" ref-type="bibr">Qasim <italic>et&#x000a0;al</italic>, 2013a</xref>). Allogeneic T cells have been shown to mediate graft-versus-leukaemia (GvL) effects following allo-SCT, but these effects are offset by the risk of graft-versus-host disease (GVHD) (<xref rid="b32" ref-type="bibr">Ho &#x00026; Soiffer, 2001</xref>). Approaches to mitigate against GVHD include expansion of T cell lines following antigenic stimulation with the aim of producing antigen-specific populations while diminishing alloreactive clones. This can take several weeks of culture but has been used to successfully treat viral reactivation after transplant, and more recently to treat leukaemic relapse (<xref rid="b9" ref-type="bibr">Chapuis <italic>et&#x000a0;al</italic>, 2013</xref>). An alternative approach to circumvent the need to culture, grow and enrich T cells in this manner is to redirect T cell specificity through the transfer of antigen receptor genes. These strategies may involve recombinant variants of conventional heterodimeric &#x003b1;&#x003b2; T cell receptor chains (TCR), or hybrid composites of antibody-like receptor chains linked to transmembrane and activation domains (CARs). Whereas &#x003b1;&#x003b2;TCRs have lower affinities and recognize processed peptide antigen expressed in the context of major histocompatibility complex (MHC), CARs are high affinity, MHC-unrestricted and capable of engaging target cell surface proteins independently of presentation pathways (<xref rid="b79" ref-type="bibr">Sadelain <italic>et&#x000a0;al</italic>, 2013</xref>). Engineering T cells to express these receptors has harnessed gene therapy technology, which enables durable gene expression following viral vector-mediated chromosomal integration of transgenes. Similar gamma-retroviral (&#x003b3;RV) and lentiviral (LV) platforms have also been used to engineer T cells for a variety of additional strategies. For example, there is now two decades of experience using &#x003b3;RV to express prodrug-activated suicide gene mechanisms derived from Herpes Simplex Thymidine kinase (HSVTK) as a contingency against GVHD, allowing elimination of mismatched T cells causing undesirable effects after allogeneic transplantation through administration of ganciclovir (<xref rid="b2" ref-type="bibr">Bonini <italic>et&#x000a0;al</italic>, 1997</xref>). Preclinical studies have also shown that T cells can be modified to resist agents such as ciclosporin (<xref rid="b6" ref-type="bibr">Brewin <italic>et&#x000a0;al</italic>, 2009</xref>), potentially allowing preservation of selected functional responses during periods of post-transplant immunosuppression and emerging technologies are exhibiting remarkable efficacy in targeted gene disruption.</p><p>In this article we update progress in the application of genetically modified T cells. The technology and processes involved in genetically modifying cells is reviewed, and recent experience from early phase clinical trials summarized, including anticipated and unanticipated adverse effects. Finally, prospects for the wider application of existing approaches are considered and emerging novel technologies for gene editing and the targeted disruption of key receptors reviewed.</p><sec><title>Genetic modification of T cells</title><p>T cells have been attractive targets for gene modification for almost three decades, being relatively easy to harvest and culture <italic>ex-vivo</italic> but researchers have encountered a variety of hurdles. T cells are hard to transfect, and given their mitotic properties, stable chromosomal integration of therapeutic genes is required for sustained effects. Non-viral gene transfer strategies have proven inefficient and require months of cell culture and co-expression of drug selection genes to produce usable yields of modified cells. In contrast, replication defective &#x003b3;RV derived from murine Moloney leukaemia virus have been used to transduce T cells since the early 1990's (<xref rid="b78" ref-type="bibr">Rosenberg <italic>et&#x000a0;al</italic>, 1990</xref>; <xref rid="b20" ref-type="bibr">Ferrari <italic>et&#x000a0;al</italic>, 1992</xref>; <xref rid="b53" ref-type="bibr">Mavilio <italic>et&#x000a0;al</italic>, 1994</xref>) with vectors devoid of packaging or envelope genes but retaining intact retroviral long terminal repeat (LTR) promoter and enhancer elements. These regions have been linked to insertional mutagenesis in gene therapy trials of inherited immune disorders where autologous haematopoietic stem cells (HSC) were transduced <italic>ex-vivo</italic> and reinfused. In severe combined immunodeficiency (SCIDX1) (<xref rid="b25" ref-type="bibr">Hacein-Bey-Abina <italic>et&#x000a0;al</italic>, 2003</xref>, <xref rid="b26" ref-type="bibr">2008</xref>; <xref rid="b33" ref-type="bibr">Howe <italic>et&#x000a0;al</italic>, 2008</xref>), Wiskott-Aldrich Syndrome (<xref rid="b3" ref-type="bibr">Braun <italic>et&#x000a0;al</italic>, 2014</xref>), and Chronic Granulomatous disease (<xref rid="b63" ref-type="bibr">Ott <italic>et&#x000a0;al</italic>, 2006</xref>); a number of subjects subsequently developed T cell or myeloid leukaemias. However, there have been no reports of similar genotoxicity in any clinical study manipulating differentiated lymphocytes, and T cells have been shown to resist retroviral-mediated transformation (<xref rid="b61" ref-type="bibr">Newrzela <italic>et&#x000a0;al</italic>, 2008</xref>). Data from longer term follow up studies have tracked engineered T cells for over a decade in patients and found no evidence of transformational effects (<xref rid="b74" ref-type="bibr">Recchia <italic>et&#x000a0;al</italic>, 2006</xref>; <xref rid="b83" ref-type="bibr">Scholler <italic>et&#x000a0;al</italic>, 2012</xref>) and in extensive pre-clinical modelling, there has only been a single report of T cell transformation in a murine T cell study using &#x003b3;RV (<xref rid="b28" ref-type="bibr">Heinrich <italic>et&#x000a0;al</italic>, 2013</xref>). As well as &#x003b3;RV, alternative LV vector systems, derived from attenuated forms of human immunodeficiency virus (HIV)-1 (<xref rid="b60" ref-type="bibr">Naldini <italic>et&#x000a0;al</italic>, 1996</xref>; <xref rid="b19" ref-type="bibr">Dull <italic>et&#x000a0;al</italic>, 1998</xref>; <xref rid="b16" ref-type="bibr">Demaison <italic>et&#x000a0;al</italic>, 2002</xref>; <xref rid="b71" ref-type="bibr">Qasim <italic>et&#x000a0;al</italic>, 2007</xref>) are now being applied for T cell engineering. These vectors are generally considered less likely to mediate genotoxicity (<xref rid="b57" ref-type="bibr">Montini <italic>et&#x000a0;al</italic>, 2009</xref>) and can be designed to incorporate elements that increase titre and gene expression (<xref rid="b19" ref-type="bibr">Dull <italic>et&#x000a0;al</italic>, 1998</xref>; <xref rid="b97" ref-type="bibr">Zufferey <italic>et&#x000a0;al</italic>, 1999</xref>; <xref rid="b16" ref-type="bibr">Demaison <italic>et&#x000a0;al</italic>, 2002</xref>). LV vectors can carry larger transgene cargos, are capable of stably transducing minimally activated T cells and preferentially integrate in active genes, without the bias towards transcription start sites exhibited by &#x003b3;RV (<xref rid="b84" ref-type="bibr">Schroder <italic>et&#x000a0;al</italic>, 2002</xref>).</p><p>One current advantage of &#x003b3;RV systems is the availability of stable vector packaging cell lines (<xref rid="b54" ref-type="bibr">Miller &#x00026; Buttimore, 1986</xref>), allowing for ready scalability of production, whereas LV stocks are produced transiently, by transfection of multiple plasmids into permissive cell lines. While LV studies are now dominating gene therapy studies targeting HSC, it is likely that both platforms will continue to be exploited for T cell modification in the foreseeable future. Other viral vector systems have had limited application for T cell therapies, but Adenovirus has been used for transient episomal gene expression sufficient for T cell modification, as recently reported in a study engineering T cells to resist HIV-1 (<xref rid="b86" ref-type="bibr">Tebas <italic>et&#x000a0;al</italic>, 2014</xref>). One alternative non-viral vector system, derived from mobile genetic elements and capable of chromosomal integration, is based on transposon transposition. Sleeping beauty (<xref rid="b36" ref-type="bibr">Ivics <italic>et&#x000a0;al</italic>, 1997</xref>) and PiggyBac (<xref rid="b18" ref-type="bibr">Ding <italic>et&#x000a0;al</italic>, 2005</xref>) transposons have been engineered to allow cut and paste chromosomal integration of antigen receptor genes (<xref rid="b35" ref-type="bibr">Ivics &#x00026; Izsvak, 2011</xref>). Therapeutic genes can be delivered by electroporation in plasmid form, flanked by inverted repeat (IR) and direct repeat (DR) sequences, which are then targeted by the sleeping beauty transposase enzyme (delivered in <italic>trans</italic> via a second plasmid). Excision and transposition of the IR/DR flanked region results in non-biased insertion of the sequence into genomic TA dinucleotide repeat sites. The strategy has been compared to LV transduction of T cells (<xref rid="b22" ref-type="bibr">Field <italic>et&#x000a0;al</italic>, 2013</xref>) and could provide a more cost-effective and streamlined approach to manufacturing, and the Sleeping Beauty system has recently been used in early phase trials of CAR19 T cell trials (see below) (<xref rid="b85" ref-type="bibr">Singh <italic>et&#x000a0;al</italic>, 2014</xref>). Additional recent developments include transfer of therapeutic genes in mRNA form, using the rationale that in certain situations, transient expression of therapeutic genes in T cells may be sufficient for useful effects (<xref rid="b96" ref-type="bibr">Zhao <italic>et&#x000a0;al</italic>, 2006</xref>). For example, transient expression of DNA nucleases allows receptor genes to be disrupted (see below) and non-sustained antigen-specific CARs may be sufficient to reduce disease burden in some conditions with a reduced risk of prolonged cytokine storms or unexpected side effects.</p><p>Quiescent T cell are relatively refractory to genetic modification and a variety of activation reagents have been used to induce T cell division, including phytohaemagglutinin, OKT3 and magnetic beads conjugated with anti-CD3 and anti-CD28 antibodies. Culture media are usually supplemented with human serum and cytokines (usually interleukin-2, IL2) and are capable of supporting T cell cultivation for several weeks. Starting material may comprise autologous or human leucocyte antigen (HLA) matched donor lymphocytes collected by venesection or by non-mobilized peripheral blood harvest. Whilst some protocols include steps to enrich CD4<sup>+</sup> or CD8<sup>+</sup> T cell subsets, or deplete CD4<sup>+</sup>&#x000a0;CD25<sup>+</sup> regulatory T cells, activation anti-CD3/anti-CD28 results in accumulation of CD3 T cells to above 90% of cultures within 48&#x02013;72&#x000a0;h and is currently the favoured method of activation. Transduction, bead removal and enrichment (where required) of engineered T cells under good manufacturing practice conditions is possible within the following 5&#x000a0;d, and readily yields sufficient cells for infusion of over 10<sup>7</sup>&#x000a0;cells/kg. Greater yields can be recovered following extended culture periods of 2&#x000a0;weeks or longer, but cells become prone to exhaustion and apoptosis. Some trials have aimed to engineer virus-specific T cells (<xref rid="b14" ref-type="bibr">Cruz <italic>et&#x000a0;al</italic>, 2013</xref>) in which populations of T cells undergo active expansion in response to challenge with autologous presenting cells expressing viral antigens, although the process can take several weeks or months.</p><p>Recent studies have investigated the optimal phenotype of T cell populations for the most effective immunotherapy. Effector memory cells can dominate cultures of transduced cells, and exhibit reduced <italic>in vivo</italic> persistence (<xref rid="b1" ref-type="bibr">Berger <italic>et&#x000a0;al</italic>, 2008</xref>). Longer-term persistence and function is provided by central memory phenotype T cells, and na&#x000ef;ve T cells retain longer telomeres and the greatest proliferative potential (<xref rid="b31" ref-type="bibr">Hinrichs <italic>et&#x000a0;al</italic>, 2011</xref>). Recently, memory stem T cells have attracted interest as populations with the greatest potential of replication and expansion (<xref rid="b23" ref-type="bibr">Gattinoni <italic>et&#x000a0;al</italic>, 2011</xref>). Targeted transduction of these populations may offer an effective, reduced cost approach to producing engineered T cells products. Whereas some early studies have aimed to infuse billions of engineered T cells following extended <italic>ex-vivo</italic> culture and expansion, more recent reports (Table&#x000a0;<xref ref-type="table" rid="tbl1">I</xref>) suggest dosing in the range of 10<sup>6</sup>&#x02013;10<sup>7</sup>/kg may be sufficient for therapeutic effect with reduced risk of infusion-related toxicities. Importantly, experience of infusing allogeneic virus-specific T cells against CMV and Adenovirus suggest that as few at 10<sup>4</sup> CD3 T cells/kg undergo <italic>in vivo</italic> expansion and are sufficient to clear pathogens (<xref rid="b67" ref-type="bibr">Peggs <italic>et&#x000a0;al</italic>, 2011</xref>; <xref rid="b72" ref-type="bibr">Qasim <italic>et&#x000a0;al</italic>, 2013a</xref>).</p><table-wrap id="tbl1" position="float"><label>Table I</label><caption><p>Recent gamma-retroviral and lentiviral trials of CAR T cell therapy against CD19.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Centre</th><th align="left" rowspan="1" colspan="1">Vector and CAR configuration</th><th align="left" rowspan="1" colspan="1">Patients/disease</th><th align="left" rowspan="1" colspan="1">Conditioning, dosing</th><th align="left" rowspan="1" colspan="1">Complications</th><th align="left" rowspan="1" colspan="1">Outcome</th><th align="left" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">UPENN</td><td align="left" rowspan="2" colspan="1">LV<break/>4-1BB, CD3&#x003b6;</td><td align="left" rowspan="1" colspan="1">3 CLL</td><td align="left" rowspan="1" colspan="1">Autologous with conditioning Cyclophosphamide<break/>Pentostatin<break/>Bendamustine<break/>Dose:10<sup>5</sup>&#x02013;10<sup>7</sup>/kg</td><td align="left" rowspan="1" colspan="1">Tumour lysis syndrome</td><td align="left" rowspan="1" colspan="1">2 CR,<break/>1 PR</td><td align="left" rowspan="2" colspan="1"><xref rid="b24" ref-type="bibr">Grupp <italic>et&#x000a0;al</italic> (2013)</xref><break/><xref rid="b40" ref-type="bibr">Kalos <italic>et&#x000a0;al</italic> (2011)</xref><break/><xref rid="b68" ref-type="bibr">Porter <italic>et&#x000a0;al</italic> (2011)</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">2 ALL</td><td align="left" rowspan="1" colspan="1">Autologous<break/>1 conditioned<break/>Cyclophoshamide<break/>Etoposide<break/>1 unconditioned<break/>Dose: 10<sup>6</sup>&#x02013;10<sup>7</sup>/kg</td><td align="left" rowspan="1" colspan="1">Cytokine release syndrome<break/>B cell aplasia</td><td align="left" rowspan="1" colspan="1">2 CR,<break/>1 durable</td></tr><tr><td align="left" rowspan="2" colspan="1">NCI</td><td align="left" rowspan="2" colspan="1">RV<break/>CD28, CD3&#x003b6;</td><td align="left" rowspan="1" colspan="1">8 B lymphomas</td><td align="left" rowspan="1" colspan="1">Cylophosphamide<break/>Fludarabine<break/>Dose: 10<sup>6</sup>&#x02013;10<sup>7</sup>/kg</td><td align="left" rowspan="1" colspan="1">Tumour lysis</td><td align="left" rowspan="1" colspan="1">6 remission</td><td align="left" rowspan="2" colspan="1"><xref rid="b45" ref-type="bibr">Kochenderfer <italic>et&#x000a0;al</italic> (2013)</xref><break/><xref rid="b44" ref-type="bibr">Kochenderfer <italic>et&#x000a0;al</italic> (2012)</xref><break/><xref rid="b43" ref-type="bibr">Kochenderfer <italic>et&#x000a0;al</italic> (2010)</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">10 post-SCT</td><td align="left" rowspan="1" colspan="1">Allogeneic post-HSCT<break/>Unconditioned</td><td align="left" rowspan="1" colspan="1">Hypotension<break/>Fever<break/>B cell aplasia</td><td align="left" rowspan="1" colspan="1">3 regression</td></tr><tr><td align="left" rowspan="2" colspan="1">MSKCC</td><td align="left" rowspan="2" colspan="1">RV<break/>CD28, CD3&#x003b6;</td><td align="left" rowspan="1" colspan="1">8 CLL<break/>1 ALL</td><td align="left" rowspan="1" colspan="1">Unconditioned or<break/>Cyclophosphamide<break/>Dose: 10<sup>6</sup>&#x02013;10<sup>7</sup>/kg</td><td align="left" rowspan="1" colspan="1">Death<break/>B cell aplasia</td><td align="left" rowspan="1" colspan="1">1 response</td><td align="left" rowspan="2" colspan="1"><xref rid="b5" ref-type="bibr">Brentjens <italic>et&#x000a0;al</italic> (2013)</xref><break/><xref rid="b4" ref-type="bibr">Brentjens <italic>et&#x000a0;al</italic> (2011)</xref><break/><xref rid="b15" ref-type="bibr">Davila <italic>et&#x000a0;al</italic> (2014)</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">5 ALL</td><td align="left" rowspan="1" colspan="1">Cyclophosphamide<break/>Dose: &#x0003c;3&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup>/kg</td><td align="left" rowspan="1" colspan="1">Cytokine release syndrome</td><td align="left" rowspan="1" colspan="1">5 MRD</td></tr><tr><td align="left" rowspan="2" colspan="1">Baylor</td><td align="left" rowspan="1" colspan="1">RV<break/>CD28, CD3&#x003b6;</td><td align="left" rowspan="1" colspan="1">8 allo-SCT</td><td align="left" rowspan="1" colspan="1">Unconditioned</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2 responses</td><td align="left" rowspan="1" colspan="1"><xref rid="b14" ref-type="bibr">Cruz <italic>et&#x000a0;al</italic> (2013)</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">RV<break/>CD3&#x003b6;<break/>CD28, CD3&#x003b6;</td><td align="left" rowspan="1" colspan="1">6 NHL</td><td align="left" rowspan="1" colspan="1">Unconditioned<break/>Dose: &#x0003c;10<sup>9</sup>/m<sup>2</sup></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2 responses</td><td align="left" rowspan="1" colspan="1"><xref rid="b81" ref-type="bibr">Savoldo <italic>et&#x000a0;al</italic> (2011)</xref></td></tr></tbody></table><table-wrap-foot><fn id="tf1-1"><p>UPENN, University of Pennsylvania; NCI, National Cancer Institute; MSKCC, Memorial Sloan Kettering Cancer Center; CAR, chimaeric antigen receptor; LV, lentiviral; RV, retroviral; CLL, chronic lymphocytic leukaemia; ALL, acute lymphoblastic leukaemia; NHL, non-Hodgkin lymphoma; SCT, stem cell transplantation; HSCT, haemopoietic stem cell transplantation; CR, complete response; PR, partial response; MRD, minimal residual disease.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Redirecting T cells to express &#x003b1;&#x003b2; antigen-specific receptors</title><p>T cells recognize antigenic peptides in the context of HLA molecules via highly diversified &#x003b1;&#x003b2; heterodimeric TCR, with CD4 T cells recognizing MHC class 1 and CD8 T cells interacting with MHC class II-presented peptide (Fig<xref ref-type="fig" rid="fig01">1</xref>). The TCR approach is limited to settings where TCR receptors against specific tumour antigen petide/HLA-combinations have been isolated from antigen-specific T cell clones. Retroviral transfer of genes encoding both the &#x003b1; and &#x003b2; TCR chains for a receptor specific for the melanoma antigen MART1 was the first to show efficacy in man. Engineered autologous T cells mediated anti-tumour effects in clinical trials of melanoma, with tumour regression in 2/15 subjects treated (<xref rid="b58" ref-type="bibr">Morgan <italic>et&#x000a0;al</italic>, 2006</xref>). Subsequent application of a higher affinity TCR against MART1 resulted in responses in 6/20 patients but anticipated &#x02018;on-target&#x02019; anti-melanin complications in skin, eyes and hair were encountered (<xref rid="b39" ref-type="bibr">Johnson <italic>et&#x000a0;al</italic>, 2009</xref>). Side effects were also reported following infusion of carcinoembryonic antigen-specific TCRs for colorectal carncinoma, where bowel inflammation developed after therapy (<xref rid="b65" ref-type="bibr">Parkhurst <italic>et&#x000a0;al</italic>, 2011</xref>). Minor toxicity was reported in another study that targeted the cancer-testis antigen NY-ESO-1 with notable tumour regression in patients with melanoma and synovial cell carcinoma (<xref rid="b77" ref-type="bibr">Robbins <italic>et&#x000a0;al</italic>, 2011</xref>). In the haematological setting, very few protein antigens have proven suitable as targets for specific immunotherapy. While common mutagenic proteins such BCR-ABL1 yield few useful HLA-associated epitopes, certain otherwise normal proteins may be aberrantly expressed on tumour cells. For example, Wilms tumour antigen 1 (WT1) is expressed in leukaemic cells including acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS), at much higher levels than in normal stem cells or other tissues. Clinical trials of TCRs directed against HLA-A2/WT1 are being planned to treat relapse of AML/MDS in centres in Japan (<xref rid="b62" ref-type="bibr">Ochi <italic>et&#x000a0;al</italic>, 2011</xref>), the USA (<xref rid="b82" ref-type="bibr">Schmitt <italic>et&#x000a0;al</italic>, 2013</xref>) and the UK (<xref rid="b93" ref-type="bibr">Xue <italic>et&#x000a0;al</italic>, 2005</xref>) The approach is supported by data from a recent experience with (non-engineered) donor-derived WT1-specific CD8 T cells infusions in post-transplant patients where antileukaemic effects were detected without notable toxicities (<xref rid="b9" ref-type="bibr">Chapuis <italic>et&#x000a0;al</italic>, 2013</xref>).</p><fig id="fig01" position="float"><label>Fig 1</label><caption><p>T cells engineered to express antigen-specific receptors can recognize and eliminate leukaemic cells. The &#x003b1;&#x003b2; T cell receptor (TCR) comprises a heterodimer that can be engineered to prevent cross-pairing with endogenous TCR chains, and is expressed in association with signalling chains of the CD3 complex. TCRs recognize specific antigenic peptides that have been processed and presented in association with human leucocyte antigen (HLA) molecules expressed on the surface of target cells. Chimaeric antigen receptors are hybrid composites derived from the antigen binding domains of antibodies, linked to CD3&#x003b6; activation domains and costimulatory moieties via transmembrane bridges. These receptors mediate high affinity binding of target cell surface proteins and are independent of HLA presentation. CAR, chimaeric antigen receptor; MHC, major histocompatibility complex.</p></caption><graphic xlink:href="bjh0166-0818-f1"/></fig><p>A similar approach is being used to transduce donor-derived T cells from CMV seronegative stem cell donors with a HLA-A0201-restricted/CMV pp65-specific T cell TCR with a view to treating transplant recipients who reactivate CMV following the procedure. The strategy is being developed to treat other viral complications including EBV (<xref rid="b27" ref-type="bibr">Hart <italic>et&#x000a0;al</italic>, 2008</xref>), and has also been used to engineer autologous T cells against Hepatitis B antigen for a patient with virus-related hepatocellular carcinoma (<xref rid="b73" ref-type="bibr">Qasim <italic>et&#x000a0;al</italic>, 2013b</xref>). These approaches are attractive in mimicking native, physiological TCRs with known activity against particular antigens, and risks of aberrant effects through cross pairing of receptor chains with endogenous receptors have been mitigated by introducing additional disulphide bridges and the use of murine constant chain domains in combination with human TCR variable regions. However, the approach is constrained in being HLA-restricted, and only a limited number of tumour-specific antigens have been defined. Strategies to modify TCR complimentarity determining regions (CDRs) to enhance the affinity and avidity of &#x003b1;&#x003b2;TCRs may address some of these limitations, albeit with undefined, and difficult to predict, risks of both &#x02018;on-target&#x02019; and &#x02018;off-target&#x02019; side effects in normal host tissue. Recent trials of a HLA-A01 restricted, affinity enhanced MAGE-A3-specific TCR uncovered serious toxicity with unexpected recognition of titin, a cardiac petide antigen in subjects being treated for melanoma and myeloma (<xref rid="b8" ref-type="bibr">Cameron <italic>et&#x000a0;al</italic>, 2013</xref>; <xref rid="b49" ref-type="bibr">Linette <italic>et&#x000a0;al</italic>, 2013</xref>). These complications arose within days of therapy and despite preclinical screening for possible cross-recognition of peptide sequences and <italic>in vitro</italic> and <italic>in vivo</italic> toxicology experiments. Similarly, unanticipated on-target neural complications have arisen because of unappreciated MAGE expression in the central nervous system (<xref rid="b59" ref-type="bibr">Morgan <italic>et&#x000a0;al</italic>, 2013</xref>).</p></sec><sec><title>T cells modified to express chimaeric antigen-specific receptors</title><p>Chimaeric antigen receptors generally comprise an extracellular antibody-derived single chain antigen-recognition domain linked to a transmembrane anchor and an intracellular signalling tail (Fig<xref ref-type="fig" rid="fig01">1</xref>). The affinity of antigen binding afforded by antibody-derived recognition is many fold stronger than that mediated by conventional &#x003b1;&#x003b2;TCRs, and CARs have the advantage of not being HLA-restricted or dependent on antigen processing and presentation (Table&#x000a0;<xref ref-type="table" rid="tbl1">II</xref>). However, only a limited number of tumour-specific targets have been defined and chimaeric receptors are non-physiological and potentially immunogenic. Transmembrane regions have been derived from CD4 or CD8 and activation regions from elements of CD3&#x003b6; in combination with CD27, CD28, 4-1BB, OX40 or other costimulatory domains (reviewed recently) (<xref rid="b79" ref-type="bibr">Sadelain <italic>et&#x000a0;al</italic>, 2013</xref>). These receptors have evolved over three decades from first generation, murine-derived receptors, to complex third generation configurations with humanized sequences which exhibit sustained <italic>in vivo</italic> persistence and antitumour activity against B cell malignancies (Table&#x000a0;<xref ref-type="table" rid="tbl1">I</xref>), neuroblastoma, (<xref rid="b64" ref-type="bibr">Park <italic>et&#x000a0;al</italic>, 2007</xref>; <xref rid="b70" ref-type="bibr">Pule <italic>et&#x000a0;al</italic>, 2008</xref>; <xref rid="b51" ref-type="bibr">Louis <italic>et&#x000a0;al</italic>, 2011</xref>) ovarian (<xref rid="b42" ref-type="bibr">Kershaw <italic>et&#x000a0;al</italic>, 2006</xref>) and renal carcinomas (<xref rid="b46" ref-type="bibr">Lamers <italic>et&#x000a0;al</italic>, 2011</xref>). The consequences of introducing additional costimulatory domains into second generation CARs have been directly compared against first generation configurations in subjects with B cell lymphomas who were infused with two autologous CD19-specific CAR-modified therapies. One included both a costimulatory CD28 and the CD3&#x003b6; activation domain, while the other encoded only the CD3&#x003b6; domain. The second generation configuration supported longer <italic>in vivo</italic> persistence and responses in 2/6 subjects with non-Hodgkin lymphoma (<xref rid="b81" ref-type="bibr">Savoldo <italic>et&#x000a0;al</italic>, 2011</xref>). Preclinical data comparing different constimulatory configurations suggested that 4-1BB signalling domains exhibited a reduced propensity to trigger IL2 and tumour necrosis factor &#x003b1; (TNF&#x003b1;) secretion (and thus precipitate cytokine release syndromes) compared to CD28 signalling domains (<xref rid="b56" ref-type="bibr">Milone <italic>et&#x000a0;al</italic>, 2009</xref>). This has been supported by early clinical data from studies using the 4-1BB regions where there has been has been a suggestion of favourable clinical outcomes (<xref rid="b40" ref-type="bibr">Kalos <italic>et&#x000a0;al</italic>, 2011</xref>) but direct comparisons in individual patients are lacking.</p><table-wrap id="tbl2" position="float"><label>Table II</label><caption><p>Comparison of TCR and CAR antigen-specific receptors.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Recombinant &#x003b1;&#x003b2; TCR</th><th align="left" rowspan="1" colspan="1">Chimaeric antigen receptors</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Cloned human TCR &#x003b1; and &#x003b2; variable regions<break/>Human or murine constant regions<break/>Additional disulphide bridge to prevent cross pairing with endogenous chains</td><td align="left" rowspan="1" colspan="1">Antibody-derived variable and constant regions<break/>Composite spacer, transmembrane and signalling domains</td></tr><tr><td align="left" rowspan="1" colspan="1">Recognize processed peptide in context of HLA</td><td align="left" rowspan="1" colspan="1">Recognize cell surface proteins independently of MHC processing or presentation</td></tr><tr><td align="left" rowspan="1" colspan="1">Low affinity binding</td><td align="left" rowspan="1" colspan="1">High affinity binding</td></tr><tr><td align="left" rowspan="1" colspan="1">Physiological signalling via the endogenous CD3 complex</td><td align="left" rowspan="1" colspan="1">Non-physiological, ectopic, CD3&#x003b6; activation</td></tr></tbody></table><table-wrap-foot><fn id="tf2-1"><p>MHC, major histocompatibility complex; TCR, T cell receptor; CAR, chimaeric antigen receptor; HLA, human leucocyte antigen.</p></fn></table-wrap-foot></table-wrap><p>Overall, targeting cell surface marker molecules expressed on the majority of B-cell malignancies (and absent on unrelated tissues) has yielded the most promising clinical results. A number of early trials used electroporation to deliver plasmids encoding first generation anti-CD20 CARs with CD3&#x003b6; activation domains linked to antibiotic resistance/drug selection genes. Extended <italic>ex-vivo</italic> culture (for several months) was required to generate target cells doses in excess of 10<sup>9</sup>/kg, which were administered after conditioning with cyclophosphamide or fludarabine (<xref rid="b88" ref-type="bibr">Till <italic>et&#x000a0;al</italic>, 2008</xref>; <xref rid="b37" ref-type="bibr">Jensen <italic>et&#x000a0;al</italic>, 2010</xref>). Use of &#x003b3;RVs expressing second-generation anti-CD19 CARs with CD3&#x003b6; and CD28 activation domains mediated clinical responses in 6/8 patients with B cell malignancies (including chronic lymphocytic leukaemia [CLL] and follicular lymphoma) (<xref rid="b43" ref-type="bibr">Kochenderfer <italic>et&#x000a0;al</italic>, 2010</xref>, <xref rid="b44" ref-type="bibr">2012</xref>). The trial used OKT3 (anti-CD3) and IL2 for autologous T cell activation and cultured cells for over 3&#x000a0;weeks, before administration of cells doses up to 3&#x000a0;&#x000d7;&#x000a0;10<sup>7</sup>/kg following lymphodepletion with cyclophosphamide or fludarabine. The same group also published data from 10 subjects who received infusions (without conditioning) of up to 7&#x000b7;8&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup>&#x000a0;cells/kg allogeneic donor T cells following allo-SCT for a variety of B cell malignancies that had persisted after conventional donor lymphocyte infusions. Three patients had disease regression and no patients developed GVHD although B cell aplasia was reported (<xref rid="b45" ref-type="bibr">Kochenderfer <italic>et&#x000a0;al</italic>, 2013</xref>). Similarly modified allogeneic T cells were also used in a trial reported by researchers at Baylor, where eight subjects received cells transduced and cultured following activation by co-culture with EBV-transformed lymphoblastoid cell lines (<xref rid="b14" ref-type="bibr">Cruz <italic>et&#x000a0;al</italic>, 2013</xref>). Again, there was no problematic GVHD but a number of subjects developed B cell lymphopenia. In the autologous setting, Memorial Sloan Kettering Cancer Center researchers have investigated similar second generation configurations, using gRV and <italic>ex-vivo</italic> transduction following activation with anti-CD3/28 beads, and included pre-conditioning with cyclophosphamide in some patients (<xref rid="b4" ref-type="bibr">Brentjens <italic>et&#x000a0;al</italic>, 2011</xref>, <xref rid="b5" ref-type="bibr">2013</xref>). A number of responses were documented and B cell aplasia reported. Some of the most promising data to date has been published by investigators at the University of Pennsylvania. Here, LV delivery of second generation CARs (with CD3&#x003b6; and 4-1BB domains) was combined with patient conditioning with combinations of cyclophosphamide, bendamustine, penotatsin and etoposide in patients with CLL and acute lymphoblastic leukaemia (ALL) (<xref rid="b40" ref-type="bibr">Kalos <italic>et&#x000a0;al</italic>, 2011</xref>; <xref rid="b68" ref-type="bibr">Porter <italic>et&#x000a0;al</italic>, 2011</xref>; <xref rid="b24" ref-type="bibr">Grupp <italic>et&#x000a0;al</italic>, 2013</xref>). Treatment was associated with remission of CLL and acute toxicities included macrophage activation syndromes and &#x02018;cytokine storms&#x02019; as discussed below. All three CLL patients developed B cell aplasia, an expected consequence of anti-CD19 therapy. The investigators calculated effector:target cell ratios in these patients and estimated that <italic>in vivo</italic> T cell expansion greater than 1000-fold contributed to antileukaemic effects through serial killing effects. One of the two paediatric patients treated for ALL using autologous CAR19-modified T cells subsequently relapsed after 2&#x000a0;months with circulating CD34<sup>+</sup>&#x000a0;CD45<sup>+dim</sup>&#x000a0;CD19<sup>&#x02212;</sup> blasts, suggesting T cell-driven selective pressure allowing emergence of CD19<sup>&#x02212;</sup> populations. This type of tumour escape phenomenon highlights an important limitation of targeting a single antigen, but also provides a rationale for simultaneously targeting additional antigens, such as CD20 and CD22 in B cell malignancies. In relapsed myeloid malignancies CD30 and CD33 may provide suitable targets, but may also be problematic if there is associated depletion of myeloid progenitors and stem cell populations. Alternative tumour-associated antigens with wider applicability include Lewis Y (LeY), a difucosylated carbohydrate antigen, which has poorly defined functions, but is expressed on a wide range of malignancies, including certain forms of AML, but has only limited expression on normal tissue. Australian investigators coupled a CAR specific for LeY to cytoplasmic domains of CD28 and the CD3-&#x003b6; chain and have undertaken an initial safety study in patients with relapsed AML, where blasts were known to express LeY (<xref rid="b76" ref-type="bibr">Ritchie <italic>et&#x000a0;al</italic>, 2013</xref>). Conditioning comprised fludarabine and four patients received up to 1&#x000b7;3&#x000a0;&#x000d7;&#x000a0;10<sup>9</sup> T cells without significant toxicity. Cytogenetic remission was achieved in one patient and protracted remission in another. Interestingly, In<sup>111</sup>-labelled CAR T cells could be tracked <italic>in vivo</italic>, and were shown to traffic to the bone marrow using single photon emission computed tomography (SPECT) imaging. Experience form allogeneic transplantation suggests certain anatomical sites may provide sanctuary against immune-mediated anti-leukaemic effects and the effectiveness of cellular immunotherapy against extra-medullary tumours, including testicular relapse or central nervous system (CNS) disease, has yet to be elucidated. Nonetheless, EBV-specific T cells can track to extramedullary sites of EBV-lymphoproliferative disease (<xref rid="b30" ref-type="bibr">Heslop <italic>et&#x000a0;al</italic>, 2010</xref>) and early trial reports suggest successful responses linked to the presence of CD19 CAR-modified T cells in cerebrospinal fluid in patients with CNS leukaemic relapse (<xref rid="b47" ref-type="bibr">Lee <italic>et&#x000a0;al</italic>, 2013</xref>).</p><p>Whilst initial non-viral approaches based on plasmid transfer were inefficient, more recently trials have commenced at the MD Anderson Cancer Center in Texas using a Sleeping Beauty transposase system for first-in-man studies. Second generation CAR19 constructs, under the control of the human EF1&#x003b1; promoter and flanked by IR/DR transposition target sequences are being used in trials of autologous and alloegenic trials against B cell malignancies (<xref rid="b85" ref-type="bibr">Singh <italic>et&#x000a0;al</italic>, 2014</xref>). The approach requires longer periods of <italic>ex-vivo</italic> culture compared to viral vector strategies, but is potentially more flexible for switching between different receptor and activation domain configurations.</p></sec><sec><title>Conferring drug sensitivity and resistance</title><p>A number of trials have established the feasibility of using T cells engineered to be sensitive to particular drugs by inclusion of a &#x02018;suicide gene&#x02019; mainly using the viral HSVTK gene linked to selection genes for antibiotic (e.g., Neomycin resistance) or magnetic bead selection (e.g., truncated forms of the low affinity nerve growth factor receptor) (<xref rid="b2" ref-type="bibr">Bonini <italic>et&#x000a0;al</italic>, 1997</xref>; <xref rid="b87" ref-type="bibr">Tiberghien <italic>et&#x000a0;al</italic>, 2001</xref>; <xref rid="b7" ref-type="bibr">Burt <italic>et&#x000a0;al</italic>, 2003</xref>; <xref rid="b10" ref-type="bibr">Ciceri <italic>et&#x000a0;al</italic>, 2007</xref>, <xref rid="b11" ref-type="bibr">2009</xref>). Such cells have been administered following mismatched or halpoidentical transplantation and trials originally initiated two decades ago in Milan have reported improved immune reconstitution and control of GVHD by using ganciclovir in a number of subjects (<xref rid="b2" ref-type="bibr">Bonini <italic>et&#x000a0;al</italic>, 1997</xref>; <xref rid="b87" ref-type="bibr">Tiberghien <italic>et&#x000a0;al</italic>, 2001</xref>; <xref rid="b7" ref-type="bibr">Burt <italic>et&#x000a0;al</italic>, 2003</xref>; <xref rid="b10" ref-type="bibr">Ciceri <italic>et&#x000a0;al</italic>, 2007</xref>, <xref rid="b11" ref-type="bibr">2009</xref>). To facilitate enrichment of suicide gene engineered cells, HSVTK has also been fused to a splice variant of human CD34, which enables rapid CliniMacs-based selection of transduced cells (<xref rid="b95" ref-type="bibr">Zhan <italic>et&#x000a0;al</italic>, 2013</xref>). Although HSVTK encodes a virally-derived protein and immune responses against engineered cells have been detected, longer-term persistence has also been reported. An alternative inducible switch, based on a fusion of human caspase-9 and a variant human FK-binding protein has also been tested in pilot studies (<xref rid="b17" ref-type="bibr">Di Stasi <italic>et&#x000a0;al</italic>, 2011</xref>). Here, suicide gene expression was linked to truncated CD19 for cell enrichment. Administration of a synthetic dimerizing drug activated caspase-mediated apoptosis of transduced cells. Similarly, expression of CD20, which can be targeted by rituximab, offers another potential avenue for targeted T cell elimination and is undergoing preclinical evaluation. Whilst these approaches have been developed primarily to allow infusion of polyclonal T cells populations whilst protecting against the risk of GVHD in allo-SCT, it is possible that they will also be included in vectors expressing novel antigen-specific receptors to safeguard against adverse effects in the autologous setting.</p><p>There have also been attempts to render T cells resistant to immunosuppressive agents, and such cells could have interesting niche applications. For example, adoptive transfer of EBV-specific T cells is an effective treatment for EBV-related lymphoproliferative disease but post-transplant immunosuppression following solid organ grafting can impair effective cellular responses. Calcineurin mutants have been designed to confer resistance to one or both of the commonly used immunosuppressants, tacrolimus and ciclosporin (<xref rid="b6" ref-type="bibr">Brewin <italic>et&#x000a0;al</italic>, 2009</xref>; <xref rid="b75" ref-type="bibr">Ricciardelli <italic>et&#x000a0;al</italic>, 2013</xref>) and proposals for pilot studies are being developed. Other approaches include rendering cells insensitive to steroids through nuclease-mediated disruption of the glucocorticoid receptor in T cells, and resistance against mycophenol phenolate through expression of mutant inosine monophosphate dehydrogenase (<xref rid="b94" ref-type="bibr">Yam <italic>et&#x000a0;al</italic>, 2006</xref>; <xref rid="b80" ref-type="bibr">Sangiolo <italic>et&#x000a0;al</italic>, 2007</xref>).</p></sec><sec><title>Host preparation and managing adverse effects</title><p>Engraftment, persistence and efficacy of engineered T cells is enhanced by the use of preparative conditioning of patients. Agents, such as cyclophosphamide, fludarabine, pentastatin and low dose irradiation, or serotherapy are all capable of mediating lymphodepletion without myeloablation. Each approach has specific related toxicities, but all increase the risk of viral reactivation and other infectious complications. Nonetheless, in the conditioned lymphopenic host, T cells undergo homeostatic expansion and are less prone to the immunosuppressive effects mediated by host regulatory T cells. Furthermore, elimination of host lymphocytes reduces the risk of host-mediated immune responses against the engineered cells that could lead to rejection, especially if encoded receptors or other transgenes include non-human or novel protein sequences. There is currently little trial data comparing the intensity of conditioning required for effective responses, and larger studies with optimal vector-receptor configurations are required to determine the most suitable preparative regimens.</p><p>Post-infusion toxicities and side effects can be considered as immediate, infusion-related events and longer term expected or unexpected consequences. Early cytokine release syndrome (CRS) in CAR therapies has been related to multiple factors including &#x003b3;-interferon (IFN&#x003b3;, TNF&#x003b1;, IL1, IL2 and IL6, and may contribute to anti-leukaemic effects, but consequential inflammation and macrophage activation syndrome (MAS) can mimic sepsis with hypotension, fever rigours and vascular leak syndromes (<xref rid="b5" ref-type="bibr">Brentjens <italic>et&#x000a0;al</italic>, 2013</xref>). Management has included supportive care and the use of methylprednisolone as well as a variety of monoclonal antibody therapies, including etanercept targeting TNF&#x003b1; and tocilizumab targeting the IL6 receptor. Differentiation from tumour lysis syndrome or bacterial sepsis may be complex, necessitating multiple therapeutic approaches. <xref rid="b15" ref-type="bibr">Davila <italic>et&#x000a0;al</italic> (2014</xref>) recently proposed diagnostic criteria defining CRS based on the presence of fever, hypotension, hypoxia or the development of neurological complications in association with a 75-fold rise in serum levels of two relevant cytokines. It is plausible that the risk of precipitating CRS may be mitigated by reducing T cell doses, or by administration of multiple, smaller dose aliquots, and by dose escalation strategies. As more data accumulates it may also be possible to identify cytokine gene polymorphisms that predispose to exaggerated inflammatory responses. Finally, a longer-term and expected consequence of using CAR therapy targeting B cell antigens has been B cell aplasia and the need for replacement immunoglobulin therapy, although this is relatively straightforward to manage.</p></sec><sec><title>Emerging tools for T cell engineering</title><p>Emerging strategies are being investigated for gene-editing rather than conventional gene-addition approaches. Molecular reagents capable of mediating highly specific DNA cleavage using targeted nucleases are providing a variety of new possibilities. Examples include zinc finger nucleases (ZFNs) (<xref rid="b91" ref-type="bibr">Urnov <italic>et&#x000a0;al</italic>, 2005</xref>; <xref rid="b50" ref-type="bibr">Lombardo <italic>et&#x000a0;al</italic>, 2007</xref>), transcription activator-like effector nucleases (TALENs)(<xref rid="b55" ref-type="bibr">Miller <italic>et&#x000a0;al</italic>, 2011</xref>) and clustered regularly interspaces short palindromic repeats (CRISPR) reagents (<xref rid="b38" ref-type="bibr">Jinek <italic>et&#x000a0;al</italic>, 2012</xref>; <xref rid="b13" ref-type="bibr">Cong <italic>et&#x000a0;al</italic>, 2013</xref>; <xref rid="b52" ref-type="bibr">Mali <italic>et&#x000a0;al</italic>, 2013</xref>) and all are under investigation for a broad spectrum of gene therapy applications. Each have specialized DNA binding elements linked to nuclease enzymes capable of DNA scission (Fig<xref ref-type="fig" rid="fig02">2</xref>). One early example of clinical application is the recent use of ZFNs targeting the <italic>CCR5</italic> gene locus in trials aiming to disrupt expression of the HIV co-receptor in T cells from subjects with the infection (<xref rid="b86" ref-type="bibr">Tebas <italic>et&#x000a0;al</italic>, 2014</xref>). Similarly, ZFNs and TALENs have been used to disrupt expression of endogenous T cell receptors in pre-clinical studies demonstrating the feasibility of generating T cells devoid of alloreactive TCRs by targeting the constant region of the TCR &#x003b1; and/or &#x003b2; chain (<xref rid="b69" ref-type="bibr">Provasi <italic>et&#x000a0;al</italic>, 2012</xref>). Introduction of antigen-specific receptors into such cells could yield populations of &#x02018;universal T cells&#x02019; that are suitable for infusion (following conditioning) into multiple HLA disparate recipients without the risk of GVHD (<xref rid="b89" ref-type="bibr">Torikai <italic>et&#x000a0;al</italic>, 2012</xref>). Similar reagents are being developed to render T cells &#x02018;invisible&#x02019; to a commonly used conditioning antibody, alemtuzemab. By disrupting CD52 expression, T cells rendered insensitive to depletion by alemtuzemab and could be infused immediately following serotherapy-conditioned transplant procedures, allowing exploitation of anti-viral or anti-leukaemia effects. Similarly, disruption of disparate HLA molecules on donor T cells may provide mitigation against host-mediated rejection (<xref rid="b90" ref-type="bibr">Torikai <italic>et&#x000a0;al</italic>, 2013</xref>). For these applications, transient expression of DNA modifying nuclease reagents in T cells is desirable (rather than integrated, permanent gene insertion) and thus electroporation of mRNA and may be sufficient for therapeutic effect. The availability of next generation high throughput sequencing will facilitate screening for off-target genomic effects including undesirable chromosomal effects resulting in translocations, rearrangements or deletions, which necessitate careful characterization and monitoring.</p><fig id="fig02" position="float"><label>Fig 2</label><caption><p>Molecular tools for gene editing are evolving and can mediate highly specific cleavage of double stranded DNA at an efficiency that is sufficient to be therapeutically useful. Zinc finger nucleases (ZFNs) are already being evaluated for disruption of the Human immunodeficiency virus co-receptor CCR5 in T cells. In common with alternative reagents based on transcription activator-like effector nucleases (TALENs), scission relies on dimerization of Fok1 endonucleases at defined genomic target sites. Recently, RNA-based DNA targeting reagents called clustered regularly interspaced short palindromic repeats (CRISPRs) have become available, and here, DNA cleavage is mediated by the enzyme Cas9. These reagents open up the possibility of designer T cells with multiple genetic modifications in combination with introduced receptors and safety/selection genes.</p></caption><graphic xlink:href="bjh0166-0818-f2"/></fig></sec><sec><title>Delivering T cells beyond trials</title><p>Harvest, isolation, activation, transduction, expansion, selection and cryopreservation of patient-derived T cells to produce bespoke medicinal therapies requires notable infrastructure and expertise. Currently only a small number of centres worldwide can provide such therapies, and generally only as part of a structured clinical trial. Notable bottlenecks include limited vector production capacity for &#x003b3;RV or LV vector stocks and difficulties in scaling production for larger trials. Differences between European and other regulatory jurisdictions provides challenges for the implementation of multicentre clinical trials and ultimately the development of licensed medicinal products, although there is increasing dialogue aimed at addressing these issues. Wider deployment will also require a notable investment in addressing the logistics of harvesting, engineering and returning T cells to patients. There are, of course, established procedures and pathways for the harvest and infusion of bone marrow and peripheral blood stem cell products and networked transplant centres, which are well placed to deliver T cell therapies if manufactured, cryopreserved and shipped from a central processing hub. In recent months there has been considerable interest and investment from pharmaceutical companies aiming to establish strategic partnerships with leading research centres. Novartis, Celgene, Juno Therapuetcis, BlueBird Bio and others are all aiming to commercialize CAR therapies, and Kite Pharma and Adaptimmune are amongst companies pursuing &#x003b1;&#x003b2;TCR-based therapies (<xref rid="b34" ref-type="bibr">Humphries, 2013</xref>). There could be rapid dissemination of CAR19-based therapies if the logistical issues are addressed, and a broadening of early phase trials assessing a variety of other target antigens in both haematological and other malignancies should follow. The implications for health care purchasers and providers have yet to unfold, but pricing is likely to attract a premium if single episode cell therapies can offer the possibility of durable benefit or cure.</p></sec><sec><title>Summary</title><p>Experience from studies using engineered T cells, including cells expressing chimaeric antigen-specific receptors, are providing proof of concept data for an emerging area of cellular therapy. Related vector platforms are being used to confer drug sensitivity and resistance, and emerging technologies are promising more sophisticated designer gene engineered T cells. Larger multi-centre trials will needed to determine which particular therapies offer the most effective interventions, and this in turn will require and number of technical and logistical hurdles to be addressed. Nonetheless, large investments are being proffered to accelerate clinical application, and prospects for T cell therapies look interesting.</p></sec></body><back><ack><p>WQ and AT wrote the manuscript and are supported by Great Ormond Street Hospital Special Trustees and receive funding from the National Institute of Health Research via the GOSH Biomedical Research Council. AT is Wellcome Trust Senior Clinical Fellow.</p></ack><sec><title>Conflicts of interest</title><p>The authors are party to collaboration and research funding agreements with the following commercial entities developing T cell therapies: Cellectis (France), Miltenyi Biotec (Germany), CellMedica (UK), Calimmune (US).</p></sec><ref-list><title>References</title><ref id="b1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>C</given-names></name><name><surname>Jensen</surname><given-names>MC</given-names></name><name><surname>Lansdorp</surname><given-names>PM</given-names></name><name><surname>Gough</surname><given-names>M</given-names></name><name><surname>Elliott</surname><given-names>C</given-names></name></person-group><person-group person-group-type="author"><name><surname>Riddell</surname><given-names>SR</given-names></name></person-group><article-title>Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates</article-title><source>J Clin Invest</source><year>2008</year><volume>118</volume><fpage>294</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">18060041</pub-id></element-citation></ref><ref id="b2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonini</surname><given-names>C</given-names></name><name><surname>Ferrari</surname><given-names>G</given-names></name><name><surname>Verzeletti</surname><given-names>S</given-names></name><name><surname>Servida</surname><given-names>P</given-names></name><name><surname>Zappone</surname><given-names>E</given-names></name><name><surname>Ruggieri</surname><given-names>L</given-names></name><name><surname>Ponzoni</surname><given-names>M</given-names></name><name><surname>Rossini</surname><given-names>S</given-names></name><name><surname>Mavilio</surname><given-names>F</given-names></name><name><surname>Traversari</surname><given-names>C</given-names></name></person-group><person-group person-group-type="author"><name><surname>Bordignon</surname><given-names>C</given-names></name></person-group><article-title>HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia</article-title><source>Science</source><year>1997</year><volume>276</volume><fpage>1719</fpage><lpage>1724</lpage><pub-id pub-id-type="pmid">9180086</pub-id></element-citation></ref><ref id="b3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braun</surname><given-names>CJ</given-names></name><name><surname>Boztug</surname><given-names>K</given-names></name><name><surname>Paruzynski</surname><given-names>A</given-names></name><name><surname>Witzel</surname><given-names>M</given-names></name><name><surname>Schwarzer</surname><given-names>A</given-names></name><name><surname>Rothe</surname><given-names>M</given-names></name><name><surname>Modlich</surname><given-names>U</given-names></name><name><surname>Beier</surname><given-names>R</given-names></name><name><surname>Gohring</surname><given-names>G</given-names></name><name><surname>Steinemann</surname><given-names>D</given-names></name><name><surname>Fronza</surname><given-names>R</given-names></name><name><surname>Ball</surname><given-names>CR</given-names></name><name><surname>Haemmerle</surname><given-names>R</given-names></name><name><surname>Naundorf</surname><given-names>S</given-names></name><name><surname>Kuhlcke</surname><given-names>K</given-names></name><name><surname>Rose</surname><given-names>M</given-names></name><name><surname>Fraser</surname><given-names>C</given-names></name><name><surname>Mathias</surname><given-names>L</given-names></name><name><surname>Ferrari</surname><given-names>R</given-names></name><name><surname>Abboud</surname><given-names>MR</given-names></name><name><surname>Al-Herz</surname><given-names>W</given-names></name><name><surname>Kondratenko</surname><given-names>I</given-names></name><name><surname>Marodi</surname><given-names>L</given-names></name><name><surname>Glimm</surname><given-names>H</given-names></name><name><surname>Schlegelberger</surname><given-names>B</given-names></name><name><surname>Schambach</surname><given-names>A</given-names></name><name><surname>Albert</surname><given-names>MH</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>von Kalle</surname><given-names>C</given-names></name></person-group><person-group person-group-type="author"><name><surname>Klein</surname><given-names>C</given-names></name></person-group><article-title>Gene therapy for wiskott-Aldrich syndrome&#x02013;long-term efficacy and genotoxicity</article-title><source>Sci Transl Med</source><year>2014</year><volume>6</volume><fpage>227ra233</fpage></element-citation></ref><ref id="b4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brentjens</surname><given-names>RJ</given-names></name><name><surname>Riviere</surname><given-names>I</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Davila</surname><given-names>ML</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Stefanski</surname><given-names>J</given-names></name><name><surname>Taylor</surname><given-names>C</given-names></name><name><surname>Yeh</surname><given-names>R</given-names></name><name><surname>Bartido</surname><given-names>S</given-names></name><name><surname>Borquez-Ojeda</surname><given-names>O</given-names></name><name><surname>Olszewska</surname><given-names>M</given-names></name><name><surname>Bernal</surname><given-names>Y</given-names></name><name><surname>Pegram</surname><given-names>H</given-names></name><name><surname>Przybylowski</surname><given-names>M</given-names></name><name><surname>Hollyman</surname><given-names>D</given-names></name><name><surname>Usachenko</surname><given-names>Y</given-names></name><name><surname>Pirraglia</surname><given-names>D</given-names></name><name><surname>Hosey</surname><given-names>J</given-names></name><name><surname>Santos</surname><given-names>E</given-names></name><name><surname>Halton</surname><given-names>E</given-names></name><name><surname>Maslak</surname><given-names>P</given-names></name><name><surname>Scheinberg</surname><given-names>D</given-names></name><name><surname>Jurcic</surname><given-names>J</given-names></name><name><surname>Heaney</surname><given-names>M</given-names></name><name><surname>Heller</surname><given-names>G</given-names></name><name><surname>Frattini</surname><given-names>M</given-names></name></person-group><person-group person-group-type="author"><name><surname>Sadelain</surname><given-names>M</given-names></name></person-group><article-title>Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias</article-title><source>Blood</source><year>2011</year><volume>118</volume><fpage>4817</fpage><lpage>4828</lpage><pub-id pub-id-type="pmid">21849486</pub-id></element-citation></ref><ref id="b5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brentjens</surname><given-names>RJ</given-names></name><name><surname>Davila</surname><given-names>ML</given-names></name><name><surname>Riviere</surname><given-names>I</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Cowell</surname><given-names>LG</given-names></name><name><surname>Bartido</surname><given-names>S</given-names></name><name><surname>Stefanski</surname><given-names>J</given-names></name><name><surname>Taylor</surname><given-names>C</given-names></name><name><surname>Olszewska</surname><given-names>M</given-names></name><name><surname>Borquez-Ojeda</surname><given-names>O</given-names></name><name><surname>Qu</surname><given-names>J</given-names></name><name><surname>Wasielewska</surname><given-names>T</given-names></name><name><surname>He</surname><given-names>Q</given-names></name><name><surname>Bernal</surname><given-names>Y</given-names></name><name><surname>Rijo</surname><given-names>IV</given-names></name><name><surname>Hedvat</surname><given-names>C</given-names></name><name><surname>Kobos</surname><given-names>R</given-names></name><name><surname>Curran</surname><given-names>K</given-names></name><name><surname>Steinherz</surname><given-names>P</given-names></name><name><surname>Jurcic</surname><given-names>J</given-names></name><name><surname>Rosenblat</surname><given-names>T</given-names></name><name><surname>Maslak</surname><given-names>P</given-names></name><name><surname>Frattini</surname><given-names>M</given-names></name></person-group><person-group person-group-type="author"><name><surname>Sadelain</surname><given-names>M</given-names></name></person-group><article-title>CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia</article-title><source>Sci Transl Med</source><year>2013</year><volume>5</volume><fpage>177ra138</fpage></element-citation></ref><ref id="b6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brewin</surname><given-names>J</given-names></name><name><surname>Mancao</surname><given-names>C</given-names></name><name><surname>Straathof</surname><given-names>K</given-names></name><name><surname>Karlsson</surname><given-names>H</given-names></name><name><surname>Samarasinghe</surname><given-names>S</given-names></name><name><surname>Amrolia</surname><given-names>PJ</given-names></name></person-group><person-group person-group-type="author"><name><surname>Pule</surname><given-names>M</given-names></name></person-group><article-title>Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease</article-title><source>Blood</source><year>2009</year><volume>114</volume><fpage>4792</fpage><lpage>4803</lpage><pub-id pub-id-type="pmid">19770360</pub-id></element-citation></ref><ref id="b7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burt</surname><given-names>RK</given-names></name><name><surname>Drobyski</surname><given-names>WR</given-names></name><name><surname>Seregina</surname><given-names>T</given-names></name><name><surname>Traynor</surname><given-names>A</given-names></name><name><surname>Oyama</surname><given-names>Y</given-names></name><name><surname>Keever-Taylor</surname><given-names>C</given-names></name><name><surname>Stefka</surname><given-names>J</given-names></name><name><surname>Kuzel</surname><given-names>TM</given-names></name><name><surname>Brush</surname><given-names>M</given-names></name><name><surname>Rodriquez</surname><given-names>J</given-names></name><name><surname>Burns</surname><given-names>W</given-names></name><name><surname>Tennant</surname><given-names>L</given-names></name></person-group><person-group person-group-type="author"><name><surname>Link</surname><given-names>C</given-names></name></person-group><article-title>Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions</article-title><source>Experimental Hematology</source><year>2003</year><volume>31</volume><fpage>903</fpage><lpage>910</lpage><pub-id pub-id-type="pmid">14550806</pub-id></element-citation></ref><ref id="b8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>BJ</given-names></name><name><surname>Gerry</surname><given-names>AB</given-names></name><name><surname>Dukes</surname><given-names>J</given-names></name><name><surname>Harper</surname><given-names>JV</given-names></name><name><surname>Kannan</surname><given-names>V</given-names></name><name><surname>Bianchi</surname><given-names>FC</given-names></name><name><surname>Grand</surname><given-names>F</given-names></name><name><surname>Brewer</surname><given-names>JE</given-names></name><name><surname>Gupta</surname><given-names>M</given-names></name><name><surname>Plesa</surname><given-names>G</given-names></name><name><surname>Bossi</surname><given-names>G</given-names></name><name><surname>Vuidepot</surname><given-names>A</given-names></name><name><surname>Powlesland</surname><given-names>AS</given-names></name><name><surname>Legg</surname><given-names>A</given-names></name><name><surname>Adams</surname><given-names>KJ</given-names></name><name><surname>Bennett</surname><given-names>AD</given-names></name><name><surname>Pumphrey</surname><given-names>NJ</given-names></name><name><surname>Williams</surname><given-names>DD</given-names></name><name><surname>Binder-Scholl</surname><given-names>G</given-names></name><name><surname>Kulikovskaya</surname><given-names>I</given-names></name><name><surname>Levine</surname><given-names>BL</given-names></name><name><surname>Riley</surname><given-names>JL</given-names></name><name><surname>Varela-Rohena</surname><given-names>A</given-names></name><name><surname>Stadtmauer</surname><given-names>EA</given-names></name><name><surname>Rapoport</surname><given-names>AP</given-names></name><name><surname>Linette</surname><given-names>GP</given-names></name><name><surname>June</surname><given-names>CH</given-names></name><name><surname>Hassan</surname><given-names>NJ</given-names></name><name><surname>Kalos</surname><given-names>M</given-names></name></person-group><person-group person-group-type="author"><name><surname>Jakobsen</surname><given-names>BK</given-names></name></person-group><article-title>Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells</article-title><source>Sci Transl Med</source><year>2013</year><volume>5</volume><fpage>197ra103</fpage></element-citation></ref><ref id="b9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapuis</surname><given-names>AG</given-names></name><name><surname>Ragnarsson</surname><given-names>GB</given-names></name><name><surname>Nguyen</surname><given-names>HN</given-names></name><name><surname>Chaney</surname><given-names>CN</given-names></name><name><surname>Pufnock</surname><given-names>JS</given-names></name><name><surname>Schmitt</surname><given-names>TM</given-names></name><name><surname>Duerkopp</surname><given-names>N</given-names></name><name><surname>Roberts</surname><given-names>IM</given-names></name><name><surname>Pogosov</surname><given-names>GL</given-names></name><name><surname>Ho</surname><given-names>WY</given-names></name><name><surname>Ochsenreither</surname><given-names>S</given-names></name><name><surname>Wolfl</surname><given-names>M</given-names></name><name><surname>Bar</surname><given-names>M</given-names></name><name><surname>Radich</surname><given-names>JP</given-names></name><name><surname>Yee</surname><given-names>C</given-names></name></person-group><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>PD</given-names></name></person-group><article-title>Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients</article-title><source>Sci Transl Med</source><year>2013</year><volume>5</volume><fpage>174ra127</fpage></element-citation></ref><ref id="b10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciceri</surname><given-names>F</given-names></name><name><surname>Bonini</surname><given-names>C</given-names></name><name><surname>Marktel</surname><given-names>S</given-names></name><name><surname>Zappone</surname><given-names>E</given-names></name><name><surname>Servida</surname><given-names>P</given-names></name><name><surname>Bernardi</surname><given-names>M</given-names></name><name><surname>Pescarollo</surname><given-names>A</given-names></name><name><surname>Bondanza</surname><given-names>A</given-names></name><name><surname>Peccatori</surname><given-names>J</given-names></name><name><surname>Rossini</surname><given-names>S</given-names></name><name><surname>Magnani</surname><given-names>Z</given-names></name><name><surname>Salomoni</surname><given-names>M</given-names></name><name><surname>Benati</surname><given-names>C</given-names></name><name><surname>Ponzoni</surname><given-names>M</given-names></name><name><surname>Callegaro</surname><given-names>L</given-names></name><name><surname>Corradini</surname><given-names>P</given-names></name><name><surname>Bregni</surname><given-names>M</given-names></name><name><surname>Traversari</surname><given-names>C</given-names></name></person-group><person-group person-group-type="author"><name><surname>Bordignon</surname><given-names>C</given-names></name></person-group><article-title>Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation</article-title><source>Blood</source><year>2007</year><volume>109</volume><fpage>4698</fpage><lpage>4707</lpage><pub-id pub-id-type="pmid">17327416</pub-id></element-citation></ref><ref id="b11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciceri</surname><given-names>F</given-names></name><name><surname>Bonini</surname><given-names>C</given-names></name><name><surname>Stanghellini</surname><given-names>MT</given-names></name><name><surname>Bondanza</surname><given-names>A</given-names></name><name><surname>Traversari</surname><given-names>C</given-names></name><name><surname>Salomoni</surname><given-names>M</given-names></name><name><surname>Turchetto</surname><given-names>L</given-names></name><name><surname>Colombi</surname><given-names>S</given-names></name><name><surname>Bernardi</surname><given-names>M</given-names></name><name><surname>Peccatori</surname><given-names>J</given-names></name><name><surname>Pescarollo</surname><given-names>A</given-names></name><name><surname>Servida</surname><given-names>P</given-names></name><name><surname>Magnani</surname><given-names>Z</given-names></name><name><surname>Perna</surname><given-names>SK</given-names></name><name><surname>Valtolina</surname><given-names>V</given-names></name><name><surname>Crippa</surname><given-names>F</given-names></name><name><surname>Callegaro</surname><given-names>L</given-names></name><name><surname>Spoldi</surname><given-names>E</given-names></name><name><surname>Crocchiolo</surname><given-names>R</given-names></name><name><surname>Fleischhauer</surname><given-names>K</given-names></name><name><surname>Ponzoni</surname><given-names>M</given-names></name><name><surname>Vago</surname><given-names>L</given-names></name><name><surname>Rossini</surname><given-names>S</given-names></name><name><surname>Santoro</surname><given-names>A</given-names></name><name><surname>Todisco</surname><given-names>E</given-names></name><name><surname>Apperley</surname><given-names>J</given-names></name><name><surname>Olavarria</surname><given-names>E</given-names></name><name><surname>Slavin</surname><given-names>S</given-names></name><name><surname>Weissinger</surname><given-names>EM</given-names></name><name><surname>Ganser</surname><given-names>A</given-names></name><name><surname>Stadler</surname><given-names>M</given-names></name><name><surname>Yannaki</surname><given-names>E</given-names></name><name><surname>Fassas</surname><given-names>A</given-names></name><name><surname>Anagnostopoulos</surname><given-names>A</given-names></name><name><surname>Bregni</surname><given-names>M</given-names></name><name><surname>Stampino</surname><given-names>CG</given-names></name><name><surname>Bruzzi</surname><given-names>P</given-names></name></person-group><person-group person-group-type="author"><name><surname>Bordignon</surname><given-names>C</given-names></name></person-group><article-title>Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I&#x02013;II study</article-title><source>Lancet Oncol</source><year>2009</year><volume>10</volume><fpage>489</fpage><lpage>500</lpage><pub-id pub-id-type="pmid">19345145</pub-id></element-citation></ref><ref id="b12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cobbold</surname><given-names>M</given-names></name><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Pourgheysari</surname><given-names>B</given-names></name><name><surname>Tauro</surname><given-names>S</given-names></name><name><surname>McDonald</surname><given-names>D</given-names></name><name><surname>Osman</surname><given-names>H</given-names></name><name><surname>Assenmacher</surname><given-names>M</given-names></name><name><surname>Billingham</surname><given-names>L</given-names></name><name><surname>Steward</surname><given-names>C</given-names></name><name><surname>Crawley</surname><given-names>C</given-names></name><name><surname>Olavarria</surname><given-names>E</given-names></name><name><surname>Goldman</surname><given-names>J</given-names></name><name><surname>Chakraverty</surname><given-names>R</given-names></name><name><surname>Mahendra</surname><given-names>P</given-names></name><name><surname>Craddock</surname><given-names>C</given-names></name></person-group><person-group person-group-type="author"><name><surname>Moss</surname><given-names>PA</given-names></name></person-group><article-title>Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers</article-title><source>Journal of Experimental Medicine</source><year>2005</year><volume>202</volume><fpage>379</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">16061727</pub-id></element-citation></ref><ref id="b13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cong</surname><given-names>L</given-names></name><name><surname>Ran</surname><given-names>FA</given-names></name><name><surname>Cox</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Barretto</surname><given-names>R</given-names></name><name><surname>Habib</surname><given-names>N</given-names></name><name><surname>Hsu</surname><given-names>PD</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Marraffini</surname><given-names>LA</given-names></name></person-group><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F</given-names></name></person-group><article-title>Multiplex genome engineering using CRISPR/Cas systems</article-title><source>Science</source><year>2013</year><volume>339</volume><fpage>819</fpage><lpage>823</lpage><pub-id pub-id-type="pmid">23287718</pub-id></element-citation></ref><ref id="b14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruz</surname><given-names>CR</given-names></name><name><surname>Micklethwaite</surname><given-names>KP</given-names></name><name><surname>Savoldo</surname><given-names>B</given-names></name><name><surname>Ramos</surname><given-names>CA</given-names></name><name><surname>Lam</surname><given-names>S</given-names></name><name><surname>Ku</surname><given-names>S</given-names></name><name><surname>Diouf</surname><given-names>O</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Barrett</surname><given-names>AJ</given-names></name><name><surname>Ito</surname><given-names>S</given-names></name><name><surname>Shpall</surname><given-names>EJ</given-names></name><name><surname>Krance</surname><given-names>RA</given-names></name><name><surname>Kamble</surname><given-names>RT</given-names></name><name><surname>Carrum</surname><given-names>G</given-names></name><name><surname>Hosing</surname><given-names>CM</given-names></name><name><surname>Gee</surname><given-names>AP</given-names></name><name><surname>Mei</surname><given-names>Z</given-names></name><name><surname>Grilley</surname><given-names>BJ</given-names></name><name><surname>Heslop</surname><given-names>HE</given-names></name><name><surname>Rooney</surname><given-names>CM</given-names></name><name><surname>Brenner</surname><given-names>MK</given-names></name><name><surname>Bollard</surname><given-names>CM</given-names></name></person-group><person-group person-group-type="author"><name><surname>Dotti</surname><given-names>G</given-names></name></person-group><article-title>Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study</article-title><source>Blood</source><year>2013</year><volume>122</volume><fpage>2965</fpage><lpage>2973</lpage><pub-id pub-id-type="pmid">24030379</pub-id></element-citation></ref><ref id="b15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davila</surname><given-names>ML</given-names></name><name><surname>Riviere</surname><given-names>I</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Bartido</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Curran</surname><given-names>K</given-names></name><name><surname>Chung</surname><given-names>SS</given-names></name><name><surname>Stefanski</surname><given-names>J</given-names></name><name><surname>Borquez-Ojeda</surname><given-names>O</given-names></name><name><surname>Olszewska</surname><given-names>M</given-names></name><name><surname>Qu</surname><given-names>J</given-names></name><name><surname>Wasielewska</surname><given-names>T</given-names></name><name><surname>He</surname><given-names>Q</given-names></name><name><surname>Fink</surname><given-names>M</given-names></name><name><surname>Shinglot</surname><given-names>H</given-names></name><name><surname>Youssif</surname><given-names>M</given-names></name><name><surname>Satter</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Hosey</surname><given-names>J</given-names></name><name><surname>Quintanilla</surname><given-names>H</given-names></name><name><surname>Halton</surname><given-names>E</given-names></name><name><surname>Bernal</surname><given-names>Y</given-names></name><name><surname>Bouhassira</surname><given-names>DC</given-names></name><name><surname>Arcila</surname><given-names>ME</given-names></name><name><surname>Gonen</surname><given-names>M</given-names></name><name><surname>Roboz</surname><given-names>GJ</given-names></name><name><surname>Maslak</surname><given-names>P</given-names></name><name><surname>Douer</surname><given-names>D</given-names></name><name><surname>Frattini</surname><given-names>MG</given-names></name><name><surname>Giralt</surname><given-names>S</given-names></name><name><surname>Sadelain</surname><given-names>M</given-names></name></person-group><person-group person-group-type="author"><name><surname>Brentjens</surname><given-names>R</given-names></name></person-group><article-title>Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia</article-title><source>Sci Transl Med</source><year>2014</year><volume>6</volume><fpage>224ra225</fpage></element-citation></ref><ref id="b16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demaison</surname><given-names>C</given-names></name><name><surname>Parsley</surname><given-names>K</given-names></name><name><surname>Brouns</surname><given-names>G</given-names></name><name><surname>Scherr</surname><given-names>M</given-names></name><name><surname>Battmer</surname><given-names>K</given-names></name><name><surname>Kinnon</surname><given-names>C</given-names></name><name><surname>Grez</surname><given-names>M</given-names></name></person-group><person-group person-group-type="author"><name><surname>Thrasher</surname><given-names>AJ</given-names></name></person-group><article-title>High-level transduction and gene expression in hematopoietic repopulating cells using a human imunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter</article-title><source>Human Gene Therapy</source><year>2002</year><volume>13</volume><fpage>803</fpage><lpage>813</lpage><pub-id pub-id-type="pmid">11975847</pub-id></element-citation></ref><ref id="b17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Stasi</surname><given-names>A</given-names></name><name><surname>Tey</surname><given-names>SK</given-names></name><name><surname>Dotti</surname><given-names>G</given-names></name><name><surname>Fujita</surname><given-names>Y</given-names></name><name><surname>Kennedy-Nasser</surname><given-names>A</given-names></name><name><surname>Martinez</surname><given-names>C</given-names></name><name><surname>Straathof</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Durett</surname><given-names>AG</given-names></name><name><surname>Grilley</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Cruz</surname><given-names>CR</given-names></name><name><surname>Savoldo</surname><given-names>B</given-names></name><name><surname>Gee</surname><given-names>AP</given-names></name><name><surname>Schindler</surname><given-names>J</given-names></name><name><surname>Krance</surname><given-names>RA</given-names></name><name><surname>Heslop</surname><given-names>HE</given-names></name><name><surname>Spencer</surname><given-names>DM</given-names></name><name><surname>Rooney</surname><given-names>CM</given-names></name></person-group><person-group person-group-type="author"><name><surname>Brenner</surname><given-names>MK</given-names></name></person-group><article-title>Inducible apoptosis as a safety switch for adoptive cell therapy</article-title><source>New England Journal of Medicine</source><year>2011</year><volume>365</volume><fpage>1673</fpage><lpage>1683</lpage><pub-id pub-id-type="pmid">22047558</pub-id></element-citation></ref><ref id="b18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Han</surname><given-names>M</given-names></name><name><surname>Zhuang</surname><given-names>Y</given-names></name></person-group><person-group person-group-type="author"><name><surname>Xu</surname><given-names>T</given-names></name></person-group><article-title>Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice</article-title><source>Cell</source><year>2005</year><volume>122</volume><fpage>473</fpage><lpage>483</lpage><pub-id pub-id-type="pmid">16096065</pub-id></element-citation></ref><ref id="b19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dull</surname><given-names>T</given-names></name><name><surname>Zufferey</surname><given-names>R</given-names></name><name><surname>Kelly</surname><given-names>M</given-names></name><name><surname>Mandel</surname><given-names>RJ</given-names></name><name><surname>Nguyen</surname><given-names>M</given-names></name><name><surname>Trono</surname><given-names>D</given-names></name></person-group><person-group person-group-type="author"><name><surname>Naldini</surname><given-names>L</given-names></name></person-group><article-title>A third-generation lentivirus vector with a conditional packaging system</article-title><source>The Journal of Virology</source><year>1998</year><volume>72</volume><fpage>8463</fpage><lpage>8471</lpage></element-citation></ref><ref id="b20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>G</given-names></name><name><surname>Rossini</surname><given-names>S</given-names></name><name><surname>Nobili</surname><given-names>N</given-names></name><name><surname>Maggioni</surname><given-names>D</given-names></name><name><surname>Garofalo</surname><given-names>A</given-names></name><name><surname>Giavazzi</surname><given-names>R</given-names></name><name><surname>Mavilio</surname><given-names>F</given-names></name></person-group><person-group person-group-type="author"><name><surname>Bordignon</surname><given-names>C</given-names></name></person-group><article-title>Transfer of the ADA gene into human ADA-deficient T lymphocytes reconstitutes specific immune functions</article-title><source>Blood</source><year>1992</year><volume>80</volume><fpage>1120</fpage><lpage>1124</lpage><pub-id pub-id-type="pmid">1325209</pub-id></element-citation></ref><ref id="b21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feuchtinger</surname><given-names>T</given-names></name><name><surname>Matthes-Martin</surname><given-names>S</given-names></name><name><surname>Richard</surname><given-names>C</given-names></name><name><surname>Lion</surname><given-names>T</given-names></name><name><surname>Fuhrer</surname><given-names>M</given-names></name><name><surname>Hamprecht</surname><given-names>K</given-names></name><name><surname>Handgretinger</surname><given-names>R</given-names></name><name><surname>Peters</surname><given-names>C</given-names></name><name><surname>Schuster</surname><given-names>FR</given-names></name><name><surname>Beck</surname><given-names>R</given-names></name><name><surname>Schumm</surname><given-names>M</given-names></name><name><surname>Lotfi</surname><given-names>R</given-names></name><name><surname>Jahn</surname><given-names>G</given-names></name></person-group><person-group person-group-type="author"><name><surname>Lang</surname><given-names>P</given-names></name></person-group><article-title>Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation</article-title><source>British Journal of Haematology</source><year>2006</year><volume>134</volume><fpage>64</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">16803570</pub-id></element-citation></ref><ref id="b22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Field</surname><given-names>AC</given-names></name><name><surname>Vink</surname><given-names>C</given-names></name><name><surname>Gabriel</surname><given-names>R</given-names></name><name><surname>Al-Subki</surname><given-names>R</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Goulden</surname><given-names>N</given-names></name><name><surname>Stauss</surname><given-names>H</given-names></name><name><surname>Thrasher</surname><given-names>A</given-names></name><name><surname>Morris</surname><given-names>E</given-names></name></person-group><person-group person-group-type="author"><name><surname>Qasim</surname><given-names>W</given-names></name></person-group><article-title>Comparison of lentiviral and sleeping beauty mediated alphabeta T cell receptor gene transfer</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><fpage>e68201</fpage><pub-id pub-id-type="pmid">23840834</pub-id></element-citation></ref><ref id="b23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gattinoni</surname><given-names>L</given-names></name><name><surname>Lugli</surname><given-names>E</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name><name><surname>Pos</surname><given-names>Z</given-names></name><name><surname>Paulos</surname><given-names>CM</given-names></name><name><surname>Quigley</surname><given-names>MF</given-names></name><name><surname>Almeida</surname><given-names>JR</given-names></name><name><surname>Gostick</surname><given-names>E</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Carpenito</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>E</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name><name><surname>Price</surname><given-names>DA</given-names></name><name><surname>June</surname><given-names>CH</given-names></name><name><surname>Marincola</surname><given-names>FM</given-names></name><name><surname>Roederer</surname><given-names>M</given-names></name></person-group><person-group person-group-type="author"><name><surname>Restifo</surname><given-names>NP</given-names></name></person-group><article-title>A human memory T cell subset with stem cell-like properties</article-title><source>Nature Medicine</source><year>2011</year><volume>17</volume><fpage>1290</fpage><lpage>1297</lpage></element-citation></ref><ref id="b24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grupp</surname><given-names>SA</given-names></name><name><surname>Kalos</surname><given-names>M</given-names></name><name><surname>Barrett</surname><given-names>D</given-names></name><name><surname>Aplenc</surname><given-names>R</given-names></name><name><surname>Porter</surname><given-names>DL</given-names></name><name><surname>Rheingold</surname><given-names>SR</given-names></name><name><surname>Teachey</surname><given-names>DT</given-names></name><name><surname>Chew</surname><given-names>A</given-names></name><name><surname>Hauck</surname><given-names>B</given-names></name><name><surname>Wright</surname><given-names>JF</given-names></name><name><surname>Milone</surname><given-names>MC</given-names></name><name><surname>Levine</surname><given-names>BL</given-names></name></person-group><person-group person-group-type="author"><name><surname>June</surname><given-names>CH</given-names></name></person-group><article-title>Chimeric antigen receptor-modified T cells for acute lymphoid leukemia</article-title><source>New England Journal of Medicine</source><year>2013</year><volume>368</volume><fpage>1509</fpage><lpage>1518</lpage><pub-id pub-id-type="pmid">23527958</pub-id></element-citation></ref><ref id="b25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hacein-Bey-Abina</surname><given-names>S</given-names></name><name><surname>Von Kalle</surname><given-names>C</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Le Deist</surname><given-names>F</given-names></name><name><surname>Wulffraat</surname><given-names>N</given-names></name><name><surname>McIntyre</surname><given-names>E</given-names></name><name><surname>Radford</surname><given-names>I</given-names></name><name><surname>Villeval</surname><given-names>JL</given-names></name><name><surname>Fraser</surname><given-names>CC</given-names></name><name><surname>Cavazzana-Calvo</surname><given-names>M</given-names></name></person-group><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>A</given-names></name></person-group><article-title>A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency</article-title><source>New England Journal of Medicine</source><year>2003</year><volume>348</volume><fpage>255</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">12529469</pub-id></element-citation></ref><ref id="b26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hacein-Bey-Abina</surname><given-names>S</given-names></name><name><surname>Garrigue</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>GP</given-names></name><name><surname>Soulier</surname><given-names>J</given-names></name><name><surname>Lim</surname><given-names>A</given-names></name><name><surname>Morillon</surname><given-names>E</given-names></name><name><surname>Clappier</surname><given-names>E</given-names></name><name><surname>Caccavelli</surname><given-names>L</given-names></name><name><surname>Delabesse</surname><given-names>E</given-names></name><name><surname>Beldjord</surname><given-names>K</given-names></name><name><surname>Asnafi</surname><given-names>V</given-names></name><name><surname>Macintyre</surname><given-names>E</given-names></name><name><surname>Dal</surname><given-names>CL</given-names></name><name><surname>Radford</surname><given-names>I</given-names></name><name><surname>Brousse</surname><given-names>N</given-names></name><name><surname>Sigaux</surname><given-names>F</given-names></name><name><surname>Moshous</surname><given-names>D</given-names></name><name><surname>Hauer</surname><given-names>J</given-names></name><name><surname>Borkhardt</surname><given-names>A</given-names></name><name><surname>Belohradsky</surname><given-names>BH</given-names></name><name><surname>Wintergerst</surname><given-names>U</given-names></name><name><surname>Velez</surname><given-names>MC</given-names></name><name><surname>Leiva</surname><given-names>L</given-names></name><name><surname>Sorensen</surname><given-names>R</given-names></name><name><surname>Wulffraat</surname><given-names>N</given-names></name><name><surname>Blanche</surname><given-names>S</given-names></name><name><surname>Bushman</surname><given-names>FD</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name></person-group><person-group person-group-type="author"><name><surname>Cavazzana-Calvo</surname><given-names>M</given-names></name></person-group><article-title>Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1</article-title><source>J. Clin. Invest</source><year>2008</year><volume>118</volume><fpage>3132</fpage><lpage>3142</lpage><pub-id pub-id-type="pmid">18688285</pub-id></element-citation></ref><ref id="b27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>DP</given-names></name><name><surname>Xue</surname><given-names>SA</given-names></name><name><surname>Thomas</surname><given-names>S</given-names></name><name><surname>Cesco-Gaspere</surname><given-names>M</given-names></name><name><surname>Tranter</surname><given-names>A</given-names></name><name><surname>Willcox</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>SP</given-names></name><name><surname>Steven</surname><given-names>N</given-names></name><name><surname>Morris</surname><given-names>EC</given-names></name></person-group><person-group person-group-type="author"><name><surname>Stauss</surname><given-names>HJ</given-names></name></person-group><article-title>Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells</article-title><source>Gene Therapy</source><year>2008</year><volume>15</volume><fpage>625</fpage><lpage>631</lpage><pub-id pub-id-type="pmid">18305579</pub-id></element-citation></ref><ref id="b28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinrich</surname><given-names>T</given-names></name><name><surname>Rengstl</surname><given-names>B</given-names></name><name><surname>Muik</surname><given-names>A</given-names></name><name><surname>Petkova</surname><given-names>M</given-names></name><name><surname>Schmid</surname><given-names>F</given-names></name><name><surname>Wistinghausen</surname><given-names>R</given-names></name><name><surname>Warner</surname><given-names>K</given-names></name><name><surname>Crispatzu</surname><given-names>G</given-names></name><name><surname>Hansmann</surname><given-names>ML</given-names></name><name><surname>Herling</surname><given-names>M</given-names></name><name><surname>von Laer</surname><given-names>D</given-names></name></person-group><person-group person-group-type="author"><name><surname>Newrzela</surname><given-names>S</given-names></name></person-group><article-title>Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1</article-title><source>Molecular Therapy</source><year>2013</year><volume>21</volume><fpage>1160</fpage><lpage>1168</lpage><pub-id pub-id-type="pmid">23609016</pub-id></element-citation></ref><ref id="b29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heslop</surname><given-names>HE</given-names></name><name><surname>Ng</surname><given-names>CY</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>CA</given-names></name><name><surname>Loftin</surname><given-names>SK</given-names></name><name><surname>Krance</surname><given-names>RA</given-names></name><name><surname>Brenner</surname><given-names>MK</given-names></name></person-group><person-group person-group-type="author"><name><surname>Rooney</surname><given-names>CM</given-names></name></person-group><article-title>Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes</article-title><source>Nature Medicine</source><year>1996</year><volume>2</volume><fpage>551</fpage><lpage>555</lpage></element-citation></ref><ref id="b30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heslop</surname><given-names>HE</given-names></name><name><surname>Slobod</surname><given-names>KS</given-names></name><name><surname>Pule</surname><given-names>MA</given-names></name><name><surname>Hale</surname><given-names>GA</given-names></name><name><surname>Rousseau</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>CA</given-names></name><name><surname>Bollard</surname><given-names>CM</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>MF</given-names></name><name><surname>Rochester</surname><given-names>RJ</given-names></name><name><surname>Amrolia</surname><given-names>PJ</given-names></name><name><surname>Hurwitz</surname><given-names>JL</given-names></name><name><surname>Brenner</surname><given-names>MK</given-names></name></person-group><person-group person-group-type="author"><name><surname>Rooney</surname><given-names>CM</given-names></name></person-group><article-title>Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients</article-title><source>Blood</source><year>2010</year><volume>115</volume><fpage>925</fpage><lpage>935</lpage><pub-id pub-id-type="pmid">19880495</pub-id></element-citation></ref><ref id="b31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinrichs</surname><given-names>CS</given-names></name><name><surname>Borman</surname><given-names>ZA</given-names></name><name><surname>Gattinoni</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Burns</surname><given-names>WR</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Klebanoff</surname><given-names>CA</given-names></name><name><surname>Johnson</surname><given-names>LA</given-names></name><name><surname>Kerkar</surname><given-names>SP</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Muranski</surname><given-names>P</given-names></name><name><surname>Palmer</surname><given-names>DC</given-names></name><name><surname>Scott</surname><given-names>CD</given-names></name><name><surname>Morgan</surname><given-names>RA</given-names></name><name><surname>Robbins</surname><given-names>PF</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><person-group person-group-type="author"><name><surname>Restifo</surname><given-names>NP</given-names></name></person-group><article-title>Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy</article-title><source>Blood</source><year>2011</year><volume>117</volume><fpage>808</fpage><lpage>814</lpage><pub-id pub-id-type="pmid">20971955</pub-id></element-citation></ref><ref id="b32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>VT</given-names></name></person-group><person-group person-group-type="author"><name><surname>Soiffer</surname><given-names>RJ</given-names></name></person-group><article-title>The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation</article-title><source>Blood</source><year>2001</year><volume>98</volume><fpage>3192</fpage><lpage>3204</lpage><pub-id pub-id-type="pmid">11719354</pub-id></element-citation></ref><ref id="b33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howe</surname><given-names>SJ</given-names></name><name><surname>Mansour</surname><given-names>MR</given-names></name><name><surname>Schwarzwaelder</surname><given-names>K</given-names></name><name><surname>Bartholomae</surname><given-names>C</given-names></name><name><surname>Hubank</surname><given-names>M</given-names></name><name><surname>Kempski</surname><given-names>H</given-names></name><name><surname>Brugman</surname><given-names>MH</given-names></name><name><surname>Pike-Overzet</surname><given-names>K</given-names></name><name><surname>Chatters</surname><given-names>SJ</given-names></name><name><surname>de Ridder</surname><given-names>D</given-names></name><name><surname>Gilmour</surname><given-names>KC</given-names></name><name><surname>Adams</surname><given-names>S</given-names></name><name><surname>Thornhill</surname><given-names>SI</given-names></name><name><surname>Parsley</surname><given-names>KL</given-names></name><name><surname>Staal</surname><given-names>FJ</given-names></name><name><surname>Gale</surname><given-names>RE</given-names></name><name><surname>Linch</surname><given-names>DC</given-names></name><name><surname>Bayford</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>L</given-names></name><name><surname>Quaye</surname><given-names>M</given-names></name><name><surname>Kinnon</surname><given-names>C</given-names></name><name><surname>Ancliff</surname><given-names>P</given-names></name><name><surname>Webb</surname><given-names>DK</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Von Kalle</surname><given-names>C</given-names></name><name><surname>Gaspar</surname><given-names>HB</given-names></name></person-group><person-group person-group-type="author"><name><surname>Thrasher</surname><given-names>AJ</given-names></name></person-group><article-title>Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients</article-title><source>J. Clin. Invest</source><year>2008</year><volume>118</volume><fpage>3143</fpage><lpage>3150</lpage><pub-id pub-id-type="pmid">18688286</pub-id></element-citation></ref><ref id="b34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humphries</surname><given-names>C</given-names></name></person-group><article-title>Adoptive cell therapy: Honing that killer instinct</article-title><source>Nature</source><year>2013</year><volume>504</volume><fpage>S13</fpage><lpage>S15</lpage><pub-id pub-id-type="pmid">24352359</pub-id></element-citation></ref><ref id="b35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivics</surname><given-names>Z</given-names></name></person-group><person-group person-group-type="author"><name><surname>Izsvak</surname><given-names>Z</given-names></name></person-group><article-title>Nonviral gene delivery with the sleeping beauty transposon system</article-title><source>Human Gene Therapy</source><year>2011</year><volume>22</volume><fpage>1043</fpage><lpage>1051</lpage><pub-id pub-id-type="pmid">21867398</pub-id></element-citation></ref><ref id="b36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivics</surname><given-names>Z</given-names></name><name><surname>Hackett</surname><given-names>PB</given-names></name><name><surname>Plasterk</surname><given-names>RH</given-names></name></person-group><person-group person-group-type="author"><name><surname>Izsvak</surname><given-names>Z</given-names></name></person-group><article-title>Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells</article-title><source>Cell</source><year>1997</year><volume>91</volume><fpage>501</fpage><lpage>510</lpage><pub-id pub-id-type="pmid">9390559</pub-id></element-citation></ref><ref id="b37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>MC</given-names></name><name><surname>Popplewell</surname><given-names>L</given-names></name><name><surname>Cooper</surname><given-names>LJ</given-names></name><name><surname>DiGiusto</surname><given-names>D</given-names></name><name><surname>Kalos</surname><given-names>M</given-names></name><name><surname>Ostberg</surname><given-names>JR</given-names></name></person-group><person-group person-group-type="author"><name><surname>Forman</surname><given-names>SJ</given-names></name></person-group><article-title>Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans</article-title><source>Biol Blood Marrow Transplant</source><year>2010</year><volume>16</volume><fpage>1245</fpage><lpage>1256</lpage><pub-id pub-id-type="pmid">20304086</pub-id></element-citation></ref><ref id="b38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jinek</surname><given-names>M</given-names></name><name><surname>Chylinski</surname><given-names>K</given-names></name><name><surname>Fonfara</surname><given-names>I</given-names></name><name><surname>Hauer</surname><given-names>M</given-names></name><name><surname>Doudna</surname><given-names>JA</given-names></name></person-group><person-group person-group-type="author"><name><surname>Charpentier</surname><given-names>E</given-names></name></person-group><article-title>A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity</article-title><source>Science</source><year>2012</year><volume>337</volume><fpage>816</fpage><lpage>821</lpage><pub-id pub-id-type="pmid">22745249</pub-id></element-citation></ref><ref id="b39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>LA</given-names></name><name><surname>Morgan</surname><given-names>RA</given-names></name><name><surname>Dudley</surname><given-names>ME</given-names></name><name><surname>Cassard</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Hughes</surname><given-names>MS</given-names></name><name><surname>Kammula</surname><given-names>US</given-names></name><name><surname>Royal</surname><given-names>RE</given-names></name><name><surname>Sherry</surname><given-names>RM</given-names></name><name><surname>Wunderlich</surname><given-names>JR</given-names></name><name><surname>Lee</surname><given-names>CC</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name><name><surname>Schwarz</surname><given-names>SL</given-names></name><name><surname>Cogdill</surname><given-names>AP</given-names></name><name><surname>Bishop</surname><given-names>RJ</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Brewer</surname><given-names>CC</given-names></name><name><surname>Rudy</surname><given-names>SF</given-names></name><name><surname>VanWaes</surname><given-names>C</given-names></name><name><surname>Davis</surname><given-names>JL</given-names></name><name><surname>Mathur</surname><given-names>A</given-names></name><name><surname>Ripley</surname><given-names>RT</given-names></name><name><surname>Nathan</surname><given-names>DA</given-names></name><name><surname>Laurencot</surname><given-names>CM</given-names></name></person-group><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen</article-title><source>Blood</source><year>2009</year><volume>114</volume><fpage>535</fpage><lpage>546</lpage><pub-id pub-id-type="pmid">19451549</pub-id></element-citation></ref><ref id="b40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalos</surname><given-names>M</given-names></name><name><surname>Levine</surname><given-names>BL</given-names></name><name><surname>Porter</surname><given-names>DL</given-names></name><name><surname>Katz</surname><given-names>S</given-names></name><name><surname>Grupp</surname><given-names>SA</given-names></name><name><surname>Bagg</surname><given-names>A</given-names></name></person-group><person-group person-group-type="author"><name><surname>June</surname><given-names>CH</given-names></name></person-group><article-title>T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia</article-title><source>Sci Transl Med</source><year>2011</year><volume>3</volume><fpage>95ra73</fpage></element-citation></ref><ref id="b41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katsnelson</surname><given-names>A</given-names></name></person-group><article-title>Drug development: target practice</article-title><source>Nature</source><year>2013</year><volume>498</volume><fpage>S8</fpage><lpage>S9</lpage><pub-id pub-id-type="pmid">23803950</pub-id></element-citation></ref><ref id="b42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kershaw</surname><given-names>MH</given-names></name><name><surname>Westwood</surname><given-names>JA</given-names></name><name><surname>Parker</surname><given-names>LL</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Eshhar</surname><given-names>Z</given-names></name><name><surname>Mavroukakis</surname><given-names>SA</given-names></name><name><surname>White</surname><given-names>DE</given-names></name><name><surname>Wunderlich</surname><given-names>JR</given-names></name><name><surname>Canevari</surname><given-names>S</given-names></name><name><surname>Rogers-Freezer</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>CC</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><person-group person-group-type="author"><name><surname>Hwu</surname><given-names>P</given-names></name></person-group><article-title>A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer</article-title><source>Clinical Cancer Research</source><year>2006</year><volume>12</volume><fpage>6106</fpage><lpage>6115</lpage><pub-id pub-id-type="pmid">17062687</pub-id></element-citation></ref><ref id="b43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kochenderfer</surname><given-names>JN</given-names></name><name><surname>Wilson</surname><given-names>WH</given-names></name><name><surname>Janik</surname><given-names>JE</given-names></name><name><surname>Dudley</surname><given-names>ME</given-names></name><name><surname>Stetler-Stevenson</surname><given-names>M</given-names></name><name><surname>Feldman</surname><given-names>SA</given-names></name><name><surname>Maric</surname><given-names>I</given-names></name><name><surname>Raffeld</surname><given-names>M</given-names></name><name><surname>Nathan</surname><given-names>DA</given-names></name><name><surname>Lanier</surname><given-names>BJ</given-names></name><name><surname>Morgan</surname><given-names>RA</given-names></name></person-group><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19</article-title><source>Blood</source><year>2010</year><volume>116</volume><fpage>4099</fpage><lpage>4102</lpage><pub-id pub-id-type="pmid">20668228</pub-id></element-citation></ref><ref id="b44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kochenderfer</surname><given-names>JN</given-names></name><name><surname>Dudley</surname><given-names>ME</given-names></name><name><surname>Feldman</surname><given-names>SA</given-names></name><name><surname>Wilson</surname><given-names>WH</given-names></name><name><surname>Spaner</surname><given-names>DE</given-names></name><name><surname>Maric</surname><given-names>I</given-names></name><name><surname>Stetler-Stevenson</surname><given-names>M</given-names></name><name><surname>Phan</surname><given-names>GQ</given-names></name><name><surname>Hughes</surname><given-names>MS</given-names></name><name><surname>Sherry</surname><given-names>RM</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Kammula</surname><given-names>US</given-names></name><name><surname>Devillier</surname><given-names>L</given-names></name><name><surname>Carpenter</surname><given-names>R</given-names></name><name><surname>Nathan</surname><given-names>DA</given-names></name><name><surname>Morgan</surname><given-names>RA</given-names></name><name><surname>Laurencot</surname><given-names>C</given-names></name></person-group><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells</article-title><source>Blood</source><year>2012</year><volume>119</volume><fpage>2709</fpage><lpage>2720</lpage><pub-id pub-id-type="pmid">22160384</pub-id></element-citation></ref><ref id="b45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kochenderfer</surname><given-names>JN</given-names></name><name><surname>Dudley</surname><given-names>ME</given-names></name><name><surname>Carpenter</surname><given-names>RO</given-names></name><name><surname>Kassim</surname><given-names>SH</given-names></name><name><surname>Rose</surname><given-names>JJ</given-names></name><name><surname>Telford</surname><given-names>WG</given-names></name><name><surname>Hakim</surname><given-names>FT</given-names></name><name><surname>Halverson</surname><given-names>DC</given-names></name><name><surname>Fowler</surname><given-names>DH</given-names></name><name><surname>Hardy</surname><given-names>NM</given-names></name><name><surname>Mato</surname><given-names>AR</given-names></name><name><surname>Hickstein</surname><given-names>DD</given-names></name><name><surname>Gea-Banacloche</surname><given-names>JC</given-names></name><name><surname>Pavletic</surname><given-names>SZ</given-names></name><name><surname>Sportes</surname><given-names>C</given-names></name><name><surname>Maric</surname><given-names>I</given-names></name><name><surname>Feldman</surname><given-names>SA</given-names></name><name><surname>Hansen</surname><given-names>BG</given-names></name><name><surname>Wilder</surname><given-names>JS</given-names></name><name><surname>Blacklock-Schuver</surname><given-names>B</given-names></name><name><surname>Jena</surname><given-names>B</given-names></name><name><surname>Bishop</surname><given-names>MR</given-names></name><name><surname>Gress</surname><given-names>RE</given-names></name></person-group><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation</article-title><source>Blood</source><year>2013</year><volume>122</volume><fpage>4129</fpage><lpage>4139</lpage><pub-id pub-id-type="pmid">24055823</pub-id></element-citation></ref><ref id="b46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamers</surname><given-names>CH</given-names></name><name><surname>Willemsen</surname><given-names>R</given-names></name><name><surname>van Elzakker</surname><given-names>P</given-names></name><name><surname>van Steenbergen-Langeveld</surname><given-names>S</given-names></name><name><surname>Broertjes</surname><given-names>M</given-names></name><name><surname>Oosterwijk-Wakka</surname><given-names>J</given-names></name><name><surname>Oosterwijk</surname><given-names>E</given-names></name><name><surname>Sleijfer</surname><given-names>S</given-names></name><name><surname>Debets</surname><given-names>R</given-names></name></person-group><person-group person-group-type="author"><name><surname>Gratama</surname><given-names>JW</given-names></name></person-group><article-title>Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells</article-title><source>Blood</source><year>2011</year><volume>117</volume><fpage>72</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">20889925</pub-id></element-citation></ref><ref id="b47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>DSN</given-names></name><name><surname>Shah</surname><given-names>NN</given-names></name><name><surname>StelerStevenson</surname><given-names>M</given-names></name><name><surname>Sabatino</surname><given-names>M</given-names></name><name><surname>Delbrook</surname><given-names>C</given-names></name><name><surname>Richards</surname><given-names>K</given-names></name><name><surname>Kockenderfer</surname><given-names>J</given-names></name><name><surname>Rosenberg</surname><given-names>S</given-names></name><name><surname>Stroncek</surname><given-names>D</given-names></name><name><surname>Wayne</surname><given-names>A</given-names></name></person-group><person-group person-group-type="author"><name><surname>Mckall</surname><given-names>C</given-names></name></person-group><article-title>Anti-CD19 Chimeric Antigen Receptor (CAR) T cells produce complete responses with acceptable toxicity but without chronic B-cell Aplasia in children with relapsed or refractory Acute Lymphoblastic Leukemia (ALL) even after allogeneic Hematopoietic Stem Cell Transplantation (HSCT)</article-title><source>Blood</source><year>2013</year><volume>122</volume><fpage>68</fpage><pub-id pub-id-type="pmid">23699599</pub-id></element-citation></ref><ref id="b48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leen</surname><given-names>AM</given-names></name><name><surname>Christin</surname><given-names>A</given-names></name><name><surname>Myers</surname><given-names>GD</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Cruz</surname><given-names>CR</given-names></name><name><surname>Hanley</surname><given-names>PJ</given-names></name><name><surname>Kennedy-Nasser</surname><given-names>AA</given-names></name><name><surname>Leung</surname><given-names>KS</given-names></name><name><surname>Gee</surname><given-names>AP</given-names></name><name><surname>Krance</surname><given-names>RA</given-names></name><name><surname>Brenner</surname><given-names>MK</given-names></name><name><surname>Heslop</surname><given-names>HE</given-names></name><name><surname>Rooney</surname><given-names>CM</given-names></name></person-group><person-group person-group-type="author"><name><surname>Bollard</surname><given-names>CM</given-names></name></person-group><article-title>Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation</article-title><source>Blood</source><year>2009</year><volume>114</volume><fpage>4283</fpage><lpage>4292</lpage><pub-id pub-id-type="pmid">19700662</pub-id></element-citation></ref><ref id="b49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linette</surname><given-names>GP</given-names></name><name><surname>Stadtmauer</surname><given-names>EA</given-names></name><name><surname>Maus</surname><given-names>MV</given-names></name><name><surname>Rapoport</surname><given-names>AP</given-names></name><name><surname>Levine</surname><given-names>BL</given-names></name><name><surname>Emery</surname><given-names>L</given-names></name><name><surname>Litzky</surname><given-names>L</given-names></name><name><surname>Bagg</surname><given-names>A</given-names></name><name><surname>Carreno</surname><given-names>BM</given-names></name><name><surname>Cimino</surname><given-names>PJ</given-names></name><name><surname>Binder-Scholl</surname><given-names>GK</given-names></name><name><surname>Smethurst</surname><given-names>DP</given-names></name><name><surname>Gerry</surname><given-names>AB</given-names></name><name><surname>Pumphrey</surname><given-names>NJ</given-names></name><name><surname>Bennett</surname><given-names>AD</given-names></name><name><surname>Brewer</surname><given-names>JE</given-names></name><name><surname>Dukes</surname><given-names>J</given-names></name><name><surname>Harper</surname><given-names>J</given-names></name><name><surname>Tayton-Martin</surname><given-names>HK</given-names></name><name><surname>Jakobsen</surname><given-names>BK</given-names></name><name><surname>Hassan</surname><given-names>NJ</given-names></name><name><surname>Kalos</surname><given-names>M</given-names></name></person-group><person-group person-group-type="author"><name><surname>June</surname><given-names>CH</given-names></name></person-group><article-title>Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma</article-title><source>Blood</source><year>2013</year><volume>122</volume><fpage>863</fpage><lpage>871</lpage><pub-id pub-id-type="pmid">23770775</pub-id></element-citation></ref><ref id="b50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lombardo</surname><given-names>A</given-names></name><name><surname>Genovese</surname><given-names>P</given-names></name><name><surname>Beausejour</surname><given-names>CM</given-names></name><name><surname>Colleoni</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>YL</given-names></name><name><surname>Kim</surname><given-names>KA</given-names></name><name><surname>Ando</surname><given-names>D</given-names></name><name><surname>Urnov</surname><given-names>FD</given-names></name><name><surname>Galli</surname><given-names>C</given-names></name><name><surname>Gregory</surname><given-names>PD</given-names></name><name><surname>Holmes</surname><given-names>MC</given-names></name></person-group><person-group person-group-type="author"><name><surname>Naldini</surname><given-names>L</given-names></name></person-group><article-title>Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery</article-title><source>Nature Biotechnology</source><year>2007</year><volume>25</volume><fpage>1298</fpage><lpage>1306</lpage></element-citation></ref><ref id="b51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louis</surname><given-names>CU</given-names></name><name><surname>Savoldo</surname><given-names>B</given-names></name><name><surname>Dotti</surname><given-names>G</given-names></name><name><surname>Pule</surname><given-names>M</given-names></name><name><surname>Yvon</surname><given-names>E</given-names></name><name><surname>Myers</surname><given-names>GD</given-names></name><name><surname>Rossig</surname><given-names>C</given-names></name><name><surname>Russell</surname><given-names>HV</given-names></name><name><surname>Diouf</surname><given-names>O</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>MF</given-names></name><name><surname>Gee</surname><given-names>AP</given-names></name><name><surname>Mei</surname><given-names>Z</given-names></name><name><surname>Rooney</surname><given-names>CM</given-names></name><name><surname>Heslop</surname><given-names>HE</given-names></name></person-group><person-group person-group-type="author"><name><surname>Brenner</surname><given-names>MK</given-names></name></person-group><article-title>Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma</article-title><source>Blood</source><year>2011</year><volume>118</volume><fpage>6050</fpage><lpage>6056</lpage><pub-id pub-id-type="pmid">21984804</pub-id></element-citation></ref><ref id="b52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mali</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Esvelt</surname><given-names>KM</given-names></name><name><surname>Aach</surname><given-names>J</given-names></name><name><surname>Guell</surname><given-names>M</given-names></name><name><surname>DiCarlo</surname><given-names>JE</given-names></name><name><surname>Norville</surname><given-names>JE</given-names></name></person-group><person-group person-group-type="author"><name><surname>Church</surname><given-names>GM</given-names></name></person-group><article-title>RNA-guided human genome engineering via Cas9</article-title><source>Science</source><year>2013</year><volume>339</volume><fpage>823</fpage><lpage>826</lpage><pub-id pub-id-type="pmid">23287722</pub-id></element-citation></ref><ref id="b53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mavilio</surname><given-names>F</given-names></name><name><surname>Ferrari</surname><given-names>G</given-names></name><name><surname>Rossini</surname><given-names>S</given-names></name><name><surname>Nobili</surname><given-names>N</given-names></name><name><surname>Bonini</surname><given-names>C</given-names></name><name><surname>Casorati</surname><given-names>G</given-names></name><name><surname>Traversari</surname><given-names>C</given-names></name></person-group><person-group person-group-type="author"><name><surname>Bordignon</surname><given-names>C</given-names></name></person-group><article-title>Peripheral blood lymphocytes as target cells of retroviral vector- mediated gene transfer</article-title><source>Blood</source><year>1994</year><volume>83</volume><fpage>1988</fpage><lpage>1997</lpage><pub-id pub-id-type="pmid">8142665</pub-id></element-citation></ref><ref id="b54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>AD</given-names></name></person-group><person-group person-group-type="author"><name><surname>Buttimore</surname><given-names>C</given-names></name></person-group><article-title>Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production</article-title><source>Molecular and Cellular Biology</source><year>1986</year><volume>6</volume><fpage>2895</fpage><lpage>2902</lpage><pub-id pub-id-type="pmid">3785217</pub-id></element-citation></ref><ref id="b55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>JC</given-names></name><name><surname>Tan</surname><given-names>S</given-names></name><name><surname>Qiao</surname><given-names>G</given-names></name><name><surname>Barlow</surname><given-names>KA</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Xia</surname><given-names>DF</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><name><surname>Paschon</surname><given-names>DE</given-names></name><name><surname>Leung</surname><given-names>E</given-names></name><name><surname>Hinkley</surname><given-names>SJ</given-names></name><name><surname>Dulay</surname><given-names>GP</given-names></name><name><surname>Hua</surname><given-names>KL</given-names></name><name><surname>Ankoudinova</surname><given-names>I</given-names></name><name><surname>Cost</surname><given-names>GJ</given-names></name><name><surname>Urnov</surname><given-names>FD</given-names></name><name><surname>Zhang</surname><given-names>HS</given-names></name><name><surname>Holmes</surname><given-names>MC</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Gregory</surname><given-names>PD</given-names></name></person-group><person-group person-group-type="author"><name><surname>Rebar</surname><given-names>EJ</given-names></name></person-group><article-title>A TALE nuclease architecture for efficient genome editing</article-title><source>Nature Biotechnology</source><year>2011</year><volume>29</volume><fpage>143</fpage><lpage>148</lpage></element-citation></ref><ref id="b56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milone</surname><given-names>MC</given-names></name><name><surname>Fish</surname><given-names>JD</given-names></name><name><surname>Carpenito</surname><given-names>C</given-names></name><name><surname>Carroll</surname><given-names>RG</given-names></name><name><surname>Binder</surname><given-names>GK</given-names></name><name><surname>Teachey</surname><given-names>D</given-names></name><name><surname>Samanta</surname><given-names>M</given-names></name><name><surname>Lakhal</surname><given-names>M</given-names></name><name><surname>Gloss</surname><given-names>B</given-names></name><name><surname>Danet-Desnoyers</surname><given-names>G</given-names></name><name><surname>Campana</surname><given-names>D</given-names></name><name><surname>Riley</surname><given-names>JL</given-names></name><name><surname>Grupp</surname><given-names>SA</given-names></name></person-group><person-group person-group-type="author"><name><surname>June</surname><given-names>CH</given-names></name></person-group><article-title>Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo</article-title><source>Molecular Therapy</source><year>2009</year><volume>17</volume><fpage>1453</fpage><lpage>1464</lpage><pub-id pub-id-type="pmid">19384291</pub-id></element-citation></ref><ref id="b57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montini</surname><given-names>E</given-names></name><name><surname>Cesana</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Sanvito</surname><given-names>F</given-names></name><name><surname>Bartholomae</surname><given-names>CC</given-names></name><name><surname>Ranzani</surname><given-names>M</given-names></name><name><surname>Benedicenti</surname><given-names>F</given-names></name><name><surname>Sergi</surname><given-names>LS</given-names></name><name><surname>Ambrosi</surname><given-names>A</given-names></name><name><surname>Ponzoni</surname><given-names>M</given-names></name><name><surname>Doglioni</surname><given-names>C</given-names></name><name><surname>Di</surname><given-names>SC</given-names></name><name><surname>von</surname><given-names>KC</given-names></name></person-group><person-group person-group-type="author"><name><surname>Naldini</surname><given-names>L</given-names></name></person-group><article-title>The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy</article-title><source>J. Clin. Invest</source><year>2009</year><volume>119</volume><fpage>964</fpage><lpage>975</lpage><pub-id pub-id-type="pmid">19307726</pub-id></element-citation></ref><ref id="b58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>RA</given-names></name><name><surname>Dudley</surname><given-names>ME</given-names></name><name><surname>Wunderlich</surname><given-names>JR</given-names></name><name><surname>Hughes</surname><given-names>MS</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Sherry</surname><given-names>RM</given-names></name><name><surname>Royal</surname><given-names>RE</given-names></name><name><surname>Topalian</surname><given-names>SL</given-names></name><name><surname>Kammula</surname><given-names>US</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Nahvi</surname><given-names>A</given-names></name><name><surname>de Vries</surname><given-names>CR</given-names></name><name><surname>Rogers-Freezer</surname><given-names>LJ</given-names></name><name><surname>Mavroukakis</surname><given-names>SA</given-names></name></person-group><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>Cancer regression in patients after transfer of genetically engineered lymphocytes</article-title><source>Science</source><year>2006</year><volume>314</volume><fpage>126</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">16946036</pub-id></element-citation></ref><ref id="b59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>RA</given-names></name><name><surname>Chinnasamy</surname><given-names>N</given-names></name><name><surname>Abate-Daga</surname><given-names>D</given-names></name><name><surname>Gros</surname><given-names>A</given-names></name><name><surname>Robbins</surname><given-names>PF</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Dudley</surname><given-names>ME</given-names></name><name><surname>Feldman</surname><given-names>SA</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Sherry</surname><given-names>RM</given-names></name><name><surname>Phan</surname><given-names>GQ</given-names></name><name><surname>Hughes</surname><given-names>MS</given-names></name><name><surname>Kammula</surname><given-names>US</given-names></name><name><surname>Miller</surname><given-names>AD</given-names></name><name><surname>Hessman</surname><given-names>CJ</given-names></name><name><surname>Stewart</surname><given-names>AA</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name><name><surname>Quezado</surname><given-names>MM</given-names></name><name><surname>Alimchandani</surname><given-names>M</given-names></name><name><surname>Rosenberg</surname><given-names>AZ</given-names></name><name><surname>Nath</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Bielekova</surname><given-names>B</given-names></name><name><surname>Wuest</surname><given-names>SC</given-names></name><name><surname>Akula</surname><given-names>N</given-names></name><name><surname>McMahon</surname><given-names>FJ</given-names></name><name><surname>Wilde</surname><given-names>S</given-names></name><name><surname>Mosetter</surname><given-names>B</given-names></name><name><surname>Schendel</surname><given-names>DJ</given-names></name><name><surname>Laurencot</surname><given-names>CM</given-names></name></person-group><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy</article-title><source>Journal of Immunotherapy</source><year>2013</year><volume>36</volume><fpage>133</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">23377668</pub-id></element-citation></ref><ref id="b60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naldini</surname><given-names>L</given-names></name><name><surname>Blomer</surname><given-names>U</given-names></name><name><surname>Gallay</surname><given-names>P</given-names></name><name><surname>Ory</surname><given-names>D</given-names></name><name><surname>Mulligan</surname><given-names>R</given-names></name><name><surname>Gage</surname><given-names>FH</given-names></name><name><surname>Verma</surname><given-names>IM</given-names></name></person-group><person-group person-group-type="author"><name><surname>Trono</surname><given-names>D</given-names></name></person-group><article-title>In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector</article-title><source>Science</source><year>1996</year><volume>272</volume><fpage>263</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">8602510</pub-id></element-citation></ref><ref id="b61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newrzela</surname><given-names>S</given-names></name><name><surname>Cornils</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Baum</surname><given-names>C</given-names></name><name><surname>Brugman</surname><given-names>MH</given-names></name><name><surname>Hartmann</surname><given-names>M</given-names></name><name><surname>Meyer</surname><given-names>J</given-names></name><name><surname>Hartmann</surname><given-names>S</given-names></name><name><surname>Hansmann</surname><given-names>ML</given-names></name><name><surname>Fehse</surname><given-names>B</given-names></name></person-group><person-group person-group-type="author"><name><surname>von Laer</surname><given-names>D</given-names></name></person-group><article-title>Resistance of mature T cells to oncogene transformation</article-title><source>Blood</source><year>2008</year><volume>112</volume><fpage>2278</fpage><lpage>2286</lpage><pub-id pub-id-type="pmid">18566328</pub-id></element-citation></ref><ref id="b62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochi</surname><given-names>T</given-names></name><name><surname>Fujiwara</surname><given-names>H</given-names></name><name><surname>Okamoto</surname><given-names>S</given-names></name><name><surname>An</surname><given-names>J</given-names></name><name><surname>Nagai</surname><given-names>K</given-names></name><name><surname>Shirakata</surname><given-names>T</given-names></name><name><surname>Mineno</surname><given-names>J</given-names></name><name><surname>Kuzushima</surname><given-names>K</given-names></name><name><surname>Shiku</surname><given-names>H</given-names></name></person-group><person-group person-group-type="author"><name><surname>Yasukawa</surname><given-names>M</given-names></name></person-group><article-title>Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety</article-title><source>Blood</source><year>2011</year><volume>118</volume><fpage>1495</fpage><lpage>1503</lpage><pub-id pub-id-type="pmid">21673345</pub-id></element-citation></ref><ref id="b63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ott</surname><given-names>MG</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Schwarzwaelder</surname><given-names>K</given-names></name><name><surname>Stein</surname><given-names>S</given-names></name><name><surname>Siler</surname><given-names>U</given-names></name><name><surname>Koehl</surname><given-names>U</given-names></name><name><surname>Glimm</surname><given-names>H</given-names></name><name><surname>Kuhlcke</surname><given-names>K</given-names></name><name><surname>Schilz</surname><given-names>A</given-names></name><name><surname>Kunkel</surname><given-names>H</given-names></name><name><surname>Naundorf</surname><given-names>S</given-names></name><name><surname>Brinkmann</surname><given-names>A</given-names></name><name><surname>Deichmann</surname><given-names>A</given-names></name><name><surname>Fischer</surname><given-names>M</given-names></name><name><surname>Ball</surname><given-names>C</given-names></name><name><surname>Pilz</surname><given-names>I</given-names></name><name><surname>Dunbar</surname><given-names>C</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Jenkins</surname><given-names>NA</given-names></name><name><surname>Copeland</surname><given-names>NG</given-names></name><name><surname>Luthi</surname><given-names>U</given-names></name><name><surname>Hassan</surname><given-names>M</given-names></name><name><surname>Thrasher</surname><given-names>AJ</given-names></name><name><surname>Hoelzer</surname><given-names>D</given-names></name><name><surname>Von Kalle</surname><given-names>C</given-names></name><name><surname>Seger</surname><given-names>R</given-names></name></person-group><person-group person-group-type="author"><name><surname>Grez</surname><given-names>M</given-names></name></person-group><article-title>Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1</article-title><source>Nature Medicine</source><year>2006</year><volume>12</volume><fpage>401</fpage><lpage>409</lpage></element-citation></ref><ref id="b64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JR</given-names></name><name><surname>Digiusto</surname><given-names>DL</given-names></name><name><surname>Slovak</surname><given-names>M</given-names></name><name><surname>Wright</surname><given-names>C</given-names></name><name><surname>Naranjo</surname><given-names>A</given-names></name><name><surname>Wagner</surname><given-names>J</given-names></name><name><surname>Meechoovet</surname><given-names>HB</given-names></name><name><surname>Bautista</surname><given-names>C</given-names></name><name><surname>Chang</surname><given-names>WC</given-names></name><name><surname>Ostberg</surname><given-names>JR</given-names></name></person-group><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>MC</given-names></name></person-group><article-title>Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma</article-title><source>Molecular Therapy</source><year>2007</year><volume>15</volume><fpage>825</fpage><lpage>833</lpage><pub-id pub-id-type="pmid">17299405</pub-id></element-citation></ref><ref id="b65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkhurst</surname><given-names>MR</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Langan</surname><given-names>RC</given-names></name><name><surname>Dudley</surname><given-names>ME</given-names></name><name><surname>Nathan</surname><given-names>DA</given-names></name><name><surname>Feldman</surname><given-names>SA</given-names></name><name><surname>Davis</surname><given-names>JL</given-names></name><name><surname>Morgan</surname><given-names>RA</given-names></name><name><surname>Merino</surname><given-names>MJ</given-names></name><name><surname>Sherry</surname><given-names>RM</given-names></name><name><surname>Hughes</surname><given-names>MS</given-names></name><name><surname>Kammula</surname><given-names>US</given-names></name><name><surname>Phan</surname><given-names>GQ</given-names></name><name><surname>Lim</surname><given-names>RM</given-names></name><name><surname>Wank</surname><given-names>SA</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name><name><surname>Robbins</surname><given-names>PF</given-names></name><name><surname>Laurencot</surname><given-names>CM</given-names></name></person-group><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis</article-title><source>Molecular Therapy</source><year>2011</year><volume>19</volume><fpage>620</fpage><lpage>626</lpage><pub-id pub-id-type="pmid">21157437</pub-id></element-citation></ref><ref id="b66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peggs</surname><given-names>KS</given-names></name><name><surname>Verfuerth</surname><given-names>S</given-names></name><name><surname>Pizzey</surname><given-names>A</given-names></name><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Guiver</surname><given-names>M</given-names></name><name><surname>Moss</surname><given-names>PA</given-names></name></person-group><person-group person-group-type="author"><name><surname>Mackinnon</surname><given-names>S</given-names></name></person-group><article-title>Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines</article-title><source>Lancet</source><year>2003</year><volume>362</volume><fpage>1375</fpage><lpage>1377</lpage><pub-id pub-id-type="pmid">14585640</pub-id></element-citation></ref><ref id="b67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peggs</surname><given-names>KS</given-names></name><name><surname>Thomson</surname><given-names>K</given-names></name><name><surname>Samuel</surname><given-names>E</given-names></name><name><surname>Dyer</surname><given-names>G</given-names></name><name><surname>Armoogum</surname><given-names>J</given-names></name><name><surname>Chakraverty</surname><given-names>R</given-names></name><name><surname>Pang</surname><given-names>K</given-names></name><name><surname>Mackinnon</surname><given-names>S</given-names></name></person-group><person-group person-group-type="author"><name><surname>Lowdell</surname><given-names>MW</given-names></name></person-group><article-title>Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation</article-title><source>Clinical Infectious Diseases</source><year>2011</year><volume>52</volume><fpage>49</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">21148519</pub-id></element-citation></ref><ref id="b68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>DL</given-names></name><name><surname>Levine</surname><given-names>BL</given-names></name><name><surname>Kalos</surname><given-names>M</given-names></name><name><surname>Bagg</surname><given-names>A</given-names></name></person-group><person-group person-group-type="author"><name><surname>June</surname><given-names>CH</given-names></name></person-group><article-title>Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia</article-title><source>New England Journal of Medicine</source><year>2011</year><volume>365</volume><fpage>725</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">21830940</pub-id></element-citation></ref><ref id="b69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Provasi</surname><given-names>E</given-names></name><name><surname>Genovese</surname><given-names>P</given-names></name><name><surname>Lombardo</surname><given-names>A</given-names></name><name><surname>Magnani</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>PQ</given-names></name><name><surname>Reik</surname><given-names>A</given-names></name><name><surname>Chu</surname><given-names>V</given-names></name><name><surname>Paschon</surname><given-names>DE</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Kuball</surname><given-names>J</given-names></name><name><surname>Camisa</surname><given-names>B</given-names></name><name><surname>Bondanza</surname><given-names>A</given-names></name><name><surname>Casorati</surname><given-names>G</given-names></name><name><surname>Ponzoni</surname><given-names>M</given-names></name><name><surname>Ciceri</surname><given-names>F</given-names></name><name><surname>Bordignon</surname><given-names>C</given-names></name><name><surname>Greenberg</surname><given-names>PD</given-names></name><name><surname>Holmes</surname><given-names>MC</given-names></name><name><surname>Gregory</surname><given-names>PD</given-names></name><name><surname>Naldini</surname><given-names>L</given-names></name></person-group><person-group person-group-type="author"><name><surname>Bonini</surname><given-names>C</given-names></name></person-group><article-title>Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer</article-title><source>Nature Medicine</source><year>2012</year><volume>18</volume><fpage>807</fpage><lpage>815</lpage></element-citation></ref><ref id="b70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pule</surname><given-names>MA</given-names></name><name><surname>Savoldo</surname><given-names>B</given-names></name><name><surname>Myers</surname><given-names>GD</given-names></name><name><surname>Rossig</surname><given-names>C</given-names></name><name><surname>Russell</surname><given-names>HV</given-names></name><name><surname>Dotti</surname><given-names>G</given-names></name><name><surname>Huls</surname><given-names>MH</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Gee</surname><given-names>AP</given-names></name><name><surname>Mei</surname><given-names>Z</given-names></name><name><surname>Yvon</surname><given-names>E</given-names></name><name><surname>Weiss</surname><given-names>HL</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Rooney</surname><given-names>CM</given-names></name><name><surname>Heslop</surname><given-names>HE</given-names></name></person-group><person-group person-group-type="author"><name><surname>Brenner</surname><given-names>MK</given-names></name></person-group><article-title>Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma</article-title><source>Nature Medicine</source><year>2008</year><volume>14</volume><fpage>1264</fpage><lpage>1270</lpage></element-citation></ref><ref id="b71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qasim</surname><given-names>W</given-names></name><name><surname>Mackey</surname><given-names>T</given-names></name><name><surname>Sinclair</surname><given-names>J</given-names></name><name><surname>Chatziandreou</surname><given-names>I</given-names></name><name><surname>Kinnon</surname><given-names>C</given-names></name><name><surname>Thrasher</surname><given-names>AJ</given-names></name></person-group><person-group person-group-type="author"><name><surname>Gaspar</surname><given-names>HB</given-names></name></person-group><article-title>Lentiviral vectors for T-cell suicide gene therapy: preservation of T-cell effector function after cytokine-mediated transduction</article-title><source>Molecular Therapy</source><year>2007</year><volume>15</volume><fpage>355</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">17235314</pub-id></element-citation></ref><ref id="b72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qasim</surname><given-names>W</given-names></name><name><surname>Gilmour</surname><given-names>K</given-names></name><name><surname>Zhan</surname><given-names>H</given-names></name><name><surname>Derniame</surname><given-names>S</given-names></name><name><surname>McNicol</surname><given-names>AM</given-names></name><name><surname>Ip</surname><given-names>W</given-names></name><name><surname>Hiwarkar</surname><given-names>P</given-names></name><name><surname>Veys</surname><given-names>P</given-names></name></person-group><person-group person-group-type="author"><name><surname>Gaspar</surname><given-names>HB</given-names></name></person-group><article-title>Interferon-gamma capture T cell therapy for persistent Adenoviraemia following allogeneic haematopoietic stem cell transplantation</article-title><source>British Journal of Haematology</source><year>2013a</year><volume>161</volume><fpage>449</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">23432400</pub-id></element-citation></ref><ref id="b73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qasim</surname><given-names>W</given-names></name><name><surname>Brunetto</surname><given-names>M</given-names></name><name><surname>Gehring</surname><given-names>A</given-names></name><name><surname>Xue</surname><given-names>SA</given-names></name><name><surname>Zhan</surname><given-names>H</given-names></name><name><surname>Ciccorossi</surname><given-names>P</given-names></name><name><surname>Gilmour</surname><given-names>K</given-names></name><name><surname>Cavallone</surname><given-names>D</given-names></name><name><surname>Moriconi</surname><given-names>F</given-names></name><name><surname>Farzhenah</surname><given-names>F</given-names></name><name><surname>Mazzoni</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>L</given-names></name><name><surname>Morris</surname><given-names>E</given-names></name><name><surname>Thrasher</surname><given-names>A</given-names></name><name><surname>Maini</surname><given-names>M</given-names></name><name><surname>Bonino</surname><given-names>F</given-names></name><name><surname>Stauss</surname><given-names>H</given-names></name></person-group><person-group person-group-type="author"><name><surname>Bertoletti</surname><given-names>A</given-names></name></person-group><article-title>Therapy with T cell receptor gene modified T cells targeting HBsAg-producing HCC metastases</article-title><source>Journal of Hepatology</source><year>2013b</year><volume>58</volume><fpage>S107</fpage></element-citation></ref><ref id="b74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Recchia</surname><given-names>A</given-names></name><name><surname>Bonini</surname><given-names>C</given-names></name><name><surname>Magnani</surname><given-names>Z</given-names></name><name><surname>Urbinati</surname><given-names>F</given-names></name><name><surname>Sartori</surname><given-names>D</given-names></name><name><surname>Muraro</surname><given-names>S</given-names></name><name><surname>Tagliafico</surname><given-names>E</given-names></name><name><surname>Bondanza</surname><given-names>A</given-names></name><name><surname>Stanghellini</surname><given-names>MT</given-names></name><name><surname>Bernardi</surname><given-names>M</given-names></name><name><surname>Pescarollo</surname><given-names>A</given-names></name><name><surname>Ciceri</surname><given-names>F</given-names></name><name><surname>Bordignon</surname><given-names>C</given-names></name></person-group><person-group person-group-type="author"><name><surname>Mavilio</surname><given-names>F</given-names></name></person-group><article-title>Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><year>2006</year><volume>103</volume><fpage>1457</fpage><lpage>1462</lpage><pub-id pub-id-type="pmid">16432223</pub-id></element-citation></ref><ref id="b75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricciardelli</surname><given-names>I</given-names></name><name><surname>Brewin</surname><given-names>J</given-names></name><name><surname>Lugthart</surname><given-names>G</given-names></name><name><surname>Albon</surname><given-names>SJ</given-names></name><name><surname>Pule</surname><given-names>M</given-names></name></person-group><person-group person-group-type="author"><name><surname>Amrolia</surname><given-names>PJ</given-names></name></person-group><article-title>Rapid generation of EBV-specific cytotoxic T lymphocytes resistant to calcineurin inhibitors for adoptive immunotherapy</article-title><source>American Journal of Transplantation</source><year>2013</year><volume>13</volume><fpage>3244</fpage><lpage>3252</lpage><pub-id pub-id-type="pmid">24266973</pub-id></element-citation></ref><ref id="b76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>DS</given-names></name><name><surname>Neeson</surname><given-names>PJ</given-names></name><name><surname>Khot</surname><given-names>A</given-names></name><name><surname>Peinert</surname><given-names>S</given-names></name><name><surname>Tai</surname><given-names>T</given-names></name><name><surname>Tainton</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Shin</surname><given-names>M</given-names></name><name><surname>Wall</surname><given-names>DM</given-names></name><name><surname>Honemann</surname><given-names>D</given-names></name><name><surname>Gambell</surname><given-names>P</given-names></name><name><surname>Westerman</surname><given-names>DA</given-names></name><name><surname>Haurat</surname><given-names>J</given-names></name><name><surname>Westwood</surname><given-names>JA</given-names></name><name><surname>Scott</surname><given-names>AM</given-names></name><name><surname>Kravets</surname><given-names>L</given-names></name><name><surname>Dickinson</surname><given-names>M</given-names></name><name><surname>Trapani</surname><given-names>JA</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Darcy</surname><given-names>PK</given-names></name><name><surname>Kershaw</surname><given-names>MH</given-names></name></person-group><person-group person-group-type="author"><name><surname>Prince</surname><given-names>HM</given-names></name></person-group><article-title>Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia</article-title><source>Molecular Therapy</source><year>2013</year><volume>21</volume><fpage>2122</fpage><lpage>2129</lpage><pub-id pub-id-type="pmid">23831595</pub-id></element-citation></ref><ref id="b77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robbins</surname><given-names>PF</given-names></name><name><surname>Morgan</surname><given-names>RA</given-names></name><name><surname>Feldman</surname><given-names>SA</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Sherry</surname><given-names>RM</given-names></name><name><surname>Dudley</surname><given-names>ME</given-names></name><name><surname>Wunderlich</surname><given-names>JR</given-names></name><name><surname>Nahvi</surname><given-names>AV</given-names></name><name><surname>Helman</surname><given-names>LJ</given-names></name><name><surname>Mackall</surname><given-names>CL</given-names></name><name><surname>Kammula</surname><given-names>US</given-names></name><name><surname>Hughes</surname><given-names>MS</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name><name><surname>Raffeld</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>CC</given-names></name><name><surname>Levy</surname><given-names>CL</given-names></name><name><surname>Li</surname><given-names>YF</given-names></name><name><surname>El-Gamil</surname><given-names>M</given-names></name><name><surname>Schwarz</surname><given-names>SL</given-names></name><name><surname>Laurencot</surname><given-names>C</given-names></name></person-group><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1</article-title><source>Journal of Clinical Oncology</source><year>2011</year><volume>29</volume><fpage>917</fpage><lpage>924</lpage><pub-id pub-id-type="pmid">21282551</pub-id></element-citation></ref><ref id="b78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Aebersold</surname><given-names>P</given-names></name><name><surname>Cornetta</surname><given-names>K</given-names></name><name><surname>Kasid</surname><given-names>A</given-names></name><name><surname>Morgan</surname><given-names>RA</given-names></name><name><surname>Moen</surname><given-names>R</given-names></name><name><surname>Karson</surname><given-names>EM</given-names></name><name><surname>Lotze</surname><given-names>MT</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name></person-group><person-group person-group-type="author"><name><surname>Topalian</surname><given-names>SL</given-names></name></person-group><article-title>Gene transfer into humans&#x02013;immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction</article-title><source>New England Journal of Medicine</source><year>1990</year><volume>323</volume><fpage>570</fpage><lpage>578</lpage><pub-id pub-id-type="pmid">2381442</pub-id></element-citation></ref><ref id="b79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadelain</surname><given-names>M</given-names></name><name><surname>Brentjens</surname><given-names>R</given-names></name></person-group><person-group person-group-type="author"><name><surname>Riviere</surname><given-names>I</given-names></name></person-group><article-title>The basic principles of chimeric antigen receptor design</article-title><source>Cancer Discov</source><year>2013</year><volume>3</volume><fpage>388</fpage><lpage>398</lpage><pub-id pub-id-type="pmid">23550147</pub-id></element-citation></ref><ref id="b80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sangiolo</surname><given-names>D</given-names></name><name><surname>Lesnikova</surname><given-names>M</given-names></name><name><surname>Nash</surname><given-names>RA</given-names></name><name><surname>Jensen</surname><given-names>MC</given-names></name><name><surname>Nikitine</surname><given-names>A</given-names></name><name><surname>Kiem</surname><given-names>HP</given-names></name></person-group><person-group person-group-type="author"><name><surname>Georges</surname><given-names>GE</given-names></name></person-group><article-title>Lentiviral vector conferring resistance to mycophenolate mofetil and sensitivity to ganciclovir for in vivo T-cell selection</article-title><source>Gene Therapy</source><year>2007</year><volume>14</volume><fpage>1549</fpage><lpage>1554</lpage><pub-id pub-id-type="pmid">17805303</pub-id></element-citation></ref><ref id="b81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savoldo</surname><given-names>B</given-names></name><name><surname>Ramos</surname><given-names>CA</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Mims</surname><given-names>MP</given-names></name><name><surname>Keating</surname><given-names>MJ</given-names></name><name><surname>Carrum</surname><given-names>G</given-names></name><name><surname>Kamble</surname><given-names>RT</given-names></name><name><surname>Bollard</surname><given-names>CM</given-names></name><name><surname>Gee</surname><given-names>AP</given-names></name><name><surname>Mei</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Grilley</surname><given-names>B</given-names></name><name><surname>Rooney</surname><given-names>CM</given-names></name><name><surname>Heslop</surname><given-names>HE</given-names></name><name><surname>Brenner</surname><given-names>MK</given-names></name></person-group><person-group person-group-type="author"><name><surname>Dotti</surname><given-names>G</given-names></name></person-group><article-title>CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients</article-title><source>J. Clin. Invest</source><year>2011</year><volume>121</volume><fpage>1822</fpage><lpage>1826</lpage><pub-id pub-id-type="pmid">21540550</pub-id></element-citation></ref><ref id="b82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>TM</given-names></name><name><surname>Aggen</surname><given-names>DH</given-names></name><name><surname>Stromnes</surname><given-names>IM</given-names></name><name><surname>Dossett</surname><given-names>ML</given-names></name><name><surname>Richman</surname><given-names>SA</given-names></name><name><surname>Kranz</surname><given-names>DM</given-names></name></person-group><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>PD</given-names></name></person-group><article-title>Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection</article-title><source>Blood</source><year>2013</year><volume>122</volume><fpage>348</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">23673862</pub-id></element-citation></ref><ref id="b83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scholler</surname><given-names>J</given-names></name><name><surname>Brady</surname><given-names>TL</given-names></name><name><surname>Binder-Scholl</surname><given-names>G</given-names></name><name><surname>Hwang</surname><given-names>WT</given-names></name><name><surname>Plesa</surname><given-names>G</given-names></name><name><surname>Hege</surname><given-names>KM</given-names></name><name><surname>Vogel</surname><given-names>AN</given-names></name><name><surname>Kalos</surname><given-names>M</given-names></name><name><surname>Riley</surname><given-names>JL</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Mitsuyasu</surname><given-names>RT</given-names></name><name><surname>Bernstein</surname><given-names>WB</given-names></name><name><surname>Aronson</surname><given-names>NE</given-names></name><name><surname>Levine</surname><given-names>BL</given-names></name><name><surname>Bushman</surname><given-names>FD</given-names></name></person-group><person-group person-group-type="author"><name><surname>June</surname><given-names>CH</given-names></name></person-group><article-title>Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells</article-title><source>Sci Transl Med</source><year>2012</year><volume>4</volume><fpage>132ra153</fpage></element-citation></ref><ref id="b84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroder</surname><given-names>AR</given-names></name><name><surname>Shinn</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Berry</surname><given-names>C</given-names></name><name><surname>Ecker</surname><given-names>JR</given-names></name></person-group><person-group person-group-type="author"><name><surname>Bushman</surname><given-names>F</given-names></name></person-group><article-title>HIV-1 integration in the human genome favors active genes and local hotspots</article-title><source>Cell</source><year>2002</year><volume>110</volume><fpage>521</fpage><lpage>529</lpage><pub-id pub-id-type="pmid">12202041</pub-id></element-citation></ref><ref id="b85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>H</given-names></name><name><surname>Huls</surname><given-names>H</given-names></name><name><surname>Kebriaei</surname><given-names>P</given-names></name></person-group><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>LJ</given-names></name></person-group><article-title>A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19</article-title><source>Immunological Reviews</source><year>2014</year><volume>257</volume><fpage>181</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">24329797</pub-id></element-citation></ref><ref id="b86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tebas</surname><given-names>P</given-names></name><name><surname>Stein</surname><given-names>D</given-names></name><name><surname>Tang</surname><given-names>WW</given-names></name><name><surname>Frank</surname><given-names>I</given-names></name><name><surname>Wang</surname><given-names>SQ</given-names></name><name><surname>Lee</surname><given-names>G</given-names></name><name><surname>Spratt</surname><given-names>SK</given-names></name><name><surname>Surosky</surname><given-names>RT</given-names></name><name><surname>Giedlin</surname><given-names>MA</given-names></name><name><surname>Nichol</surname><given-names>G</given-names></name><name><surname>Holmes</surname><given-names>MC</given-names></name><name><surname>Gregory</surname><given-names>PD</given-names></name><name><surname>Ando</surname><given-names>DG</given-names></name><name><surname>Kalos</surname><given-names>M</given-names></name><name><surname>Collman</surname><given-names>RG</given-names></name><name><surname>Binder-Scholl</surname><given-names>G</given-names></name><name><surname>Plesa</surname><given-names>G</given-names></name><name><surname>Hwang</surname><given-names>WT</given-names></name><name><surname>Levine</surname><given-names>BL</given-names></name></person-group><person-group person-group-type="author"><name><surname>June</surname><given-names>CH</given-names></name></person-group><article-title>Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV</article-title><source>New England Journal of Medicine</source><year>2014</year><volume>370</volume><fpage>901</fpage><lpage>910</lpage><pub-id pub-id-type="pmid">24597865</pub-id></element-citation></ref><ref id="b87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiberghien</surname><given-names>P</given-names></name><name><surname>Ferrand</surname><given-names>C</given-names></name><name><surname>Lioure</surname><given-names>B</given-names></name><name><surname>Milpied</surname><given-names>N</given-names></name><name><surname>Angonin</surname><given-names>R</given-names></name><name><surname>Deconinck</surname><given-names>E</given-names></name><name><surname>Certoux</surname><given-names>JM</given-names></name><name><surname>Robinet</surname><given-names>E</given-names></name><name><surname>Saas</surname><given-names>P</given-names></name><name><surname>Petracca</surname><given-names>B</given-names></name><name><surname>Juttner</surname><given-names>C</given-names></name><name><surname>Reynolds</surname><given-names>CW</given-names></name><name><surname>Longo</surname><given-names>DL</given-names></name><name><surname>Herve</surname><given-names>P</given-names></name></person-group><person-group person-group-type="author"><name><surname>Cahn</surname><given-names>JY</given-names></name></person-group><article-title>Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft</article-title><source>Blood</source><year>2001</year><volume>97</volume><fpage>63</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">11133743</pub-id></element-citation></ref><ref id="b88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Till</surname><given-names>BG</given-names></name><name><surname>Jensen</surname><given-names>MC</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>EY</given-names></name><name><surname>Wood</surname><given-names>BL</given-names></name><name><surname>Greisman</surname><given-names>HA</given-names></name><name><surname>Qian</surname><given-names>X</given-names></name><name><surname>James</surname><given-names>SE</given-names></name><name><surname>Raubitschek</surname><given-names>A</given-names></name><name><surname>Forman</surname><given-names>SJ</given-names></name><name><surname>Gopal</surname><given-names>AK</given-names></name><name><surname>Pagel</surname><given-names>JM</given-names></name><name><surname>Lindgren</surname><given-names>CG</given-names></name><name><surname>Greenberg</surname><given-names>PD</given-names></name><name><surname>Riddell</surname><given-names>SR</given-names></name></person-group><person-group person-group-type="author"><name><surname>Press</surname><given-names>OW</given-names></name></person-group><article-title>Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells</article-title><source>Blood</source><year>2008</year><volume>112</volume><fpage>2261</fpage><lpage>2271</lpage><pub-id pub-id-type="pmid">18509084</pub-id></element-citation></ref><ref id="b89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torikai</surname><given-names>H</given-names></name><name><surname>Reik</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>PQ</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Maiti</surname><given-names>S</given-names></name><name><surname>Huls</surname><given-names>H</given-names></name><name><surname>Miller</surname><given-names>JC</given-names></name><name><surname>Kebriaei</surname><given-names>P</given-names></name><name><surname>Rabinovitch</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>DA</given-names></name><name><surname>Champlin</surname><given-names>RE</given-names></name><name><surname>Bonini</surname><given-names>C</given-names></name><name><surname>Naldini</surname><given-names>L</given-names></name><name><surname>Rebar</surname><given-names>EJ</given-names></name><name><surname>Gregory</surname><given-names>PD</given-names></name><name><surname>Holmes</surname><given-names>MC</given-names></name></person-group><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>LJ</given-names></name></person-group><article-title>A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR</article-title><source>Blood</source><year>2012</year><volume>119</volume><fpage>5697</fpage><lpage>5705</lpage><pub-id pub-id-type="pmid">22535661</pub-id></element-citation></ref><ref id="b90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torikai</surname><given-names>H</given-names></name><name><surname>Reik</surname><given-names>A</given-names></name><name><surname>Soldner</surname><given-names>F</given-names></name><name><surname>Warren</surname><given-names>EH</given-names></name><name><surname>Yuen</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Crossland</surname><given-names>DL</given-names></name><name><surname>Huls</surname><given-names>H</given-names></name><name><surname>Littman</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Tykodi</surname><given-names>SS</given-names></name><name><surname>Kebriaei</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>DA</given-names></name><name><surname>Miller</surname><given-names>JC</given-names></name><name><surname>Rebar</surname><given-names>EJ</given-names></name><name><surname>Holmes</surname><given-names>MC</given-names></name><name><surname>Jaenisch</surname><given-names>R</given-names></name><name><surname>Champlin</surname><given-names>RE</given-names></name><name><surname>Gregory</surname><given-names>PD</given-names></name></person-group><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>LJ</given-names></name></person-group><article-title>Toward eliminating HLA class I expression to generate universal cells from allogeneic donors</article-title><source>Blood</source><year>2013</year><volume>122</volume><fpage>1341</fpage><lpage>1349</lpage><pub-id pub-id-type="pmid">23741009</pub-id></element-citation></ref><ref id="b91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urnov</surname><given-names>FD</given-names></name><name><surname>Miller</surname><given-names>JC</given-names></name><name><surname>Lee</surname><given-names>YL</given-names></name><name><surname>Beausejour</surname><given-names>CM</given-names></name><name><surname>Rock</surname><given-names>JM</given-names></name><name><surname>Augustus</surname><given-names>S</given-names></name><name><surname>Jamieson</surname><given-names>AC</given-names></name><name><surname>Porteus</surname><given-names>MH</given-names></name><name><surname>Gregory</surname><given-names>PD</given-names></name></person-group><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>MC</given-names></name></person-group><article-title>Highly efficient endogenous human gene correction using designed zinc-finger nucleases</article-title><source>Nature</source><year>2005</year><volume>435</volume><fpage>646</fpage><lpage>651</lpage><pub-id pub-id-type="pmid">15806097</pub-id></element-citation></ref><ref id="b92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walter</surname><given-names>EA</given-names></name><name><surname>Greenberg</surname><given-names>PD</given-names></name><name><surname>Gilbert</surname><given-names>MJ</given-names></name><name><surname>Finch</surname><given-names>RJ</given-names></name><name><surname>Watanabe</surname><given-names>KS</given-names></name><name><surname>Thomas</surname><given-names>ED</given-names></name></person-group><person-group person-group-type="author"><name><surname>Riddell</surname><given-names>SR</given-names></name></person-group><article-title>Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor</article-title><source>New England Journal of Medicine</source><year>1995</year><volume>333</volume><fpage>1038</fpage><lpage>1044</lpage><pub-id pub-id-type="pmid">7675046</pub-id></element-citation></ref><ref id="b93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>SA</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Hart</surname><given-names>D</given-names></name><name><surname>Gillmore</surname><given-names>R</given-names></name><name><surname>Qasim</surname><given-names>W</given-names></name><name><surname>Thrasher</surname><given-names>A</given-names></name><name><surname>Apperley</surname><given-names>J</given-names></name><name><surname>Engels</surname><given-names>B</given-names></name><name><surname>Uckert</surname><given-names>W</given-names></name><name><surname>Morris</surname><given-names>E</given-names></name></person-group><person-group person-group-type="author"><name><surname>Stauss</surname><given-names>HJ</given-names></name></person-group><article-title>Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene transduced human T cells</article-title><source>Blood</source><year>2005</year><volume>106</volume><fpage>3062</fpage><lpage>3067</lpage><pub-id pub-id-type="pmid">16020516</pub-id></element-citation></ref><ref id="b94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yam</surname><given-names>P</given-names></name><name><surname>Jensen</surname><given-names>M</given-names></name><name><surname>Akkina</surname><given-names>R</given-names></name><name><surname>Anderson</surname><given-names>J</given-names></name><name><surname>Villacres</surname><given-names>MC</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Zaia</surname><given-names>JA</given-names></name></person-group><person-group person-group-type="author"><name><surname>Yee</surname><given-names>JK</given-names></name></person-group><article-title>Ex vivo selection and expansion of cells based on expression of a mutated inosine monophosphate dehydrogenase 2 after HIV vector transduction: effects on lymphocytes, monocytes, and CD34+ stem cells</article-title><source>Molecular Therapy</source><year>2006</year><volume>14</volume><fpage>236</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">16647299</pub-id></element-citation></ref><ref id="b95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhan</surname><given-names>H</given-names></name><name><surname>Gilmour</surname><given-names>K</given-names></name><name><surname>Chan</surname><given-names>L</given-names></name><name><surname>Farzaneh</surname><given-names>F</given-names></name><name><surname>McNicol</surname><given-names>AM</given-names></name><name><surname>Xu</surname><given-names>JH</given-names></name><name><surname>Adams</surname><given-names>S</given-names></name><name><surname>Fehse</surname><given-names>B</given-names></name><name><surname>Veys</surname><given-names>P</given-names></name><name><surname>Thrasher</surname><given-names>A</given-names></name><name><surname>Gaspar</surname><given-names>H</given-names></name></person-group><person-group person-group-type="author"><name><surname>Qasim</surname><given-names>W</given-names></name></person-group><article-title>Production and first-in-man use of T cells engineered to express a HSVTK-CD34 sort-suicide gene</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><fpage>e77106</fpage><pub-id pub-id-type="pmid">24204746</pub-id></element-citation></ref><ref id="b96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Cohen</surname><given-names>CJ</given-names></name><name><surname>Gattinoni</surname><given-names>L</given-names></name><name><surname>Palmer</surname><given-names>DC</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>RA</given-names></name></person-group><article-title>High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation</article-title><source>Molecular Therapy</source><year>2006</year><volume>13</volume><fpage>151</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">16140584</pub-id></element-citation></ref><ref id="b97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zufferey</surname><given-names>R</given-names></name><name><surname>Donello</surname><given-names>JE</given-names></name><name><surname>Trono</surname><given-names>D</given-names></name></person-group><person-group person-group-type="author"><name><surname>Hope</surname><given-names>TJ</given-names></name></person-group><article-title>Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors</article-title><source>The Journal of Virology</source><year>1999</year><volume>73</volume><fpage>2886</fpage><lpage>2892</lpage></element-citation></ref></ref-list></back></article>